Group ID|Group Name|Treatment Sequence|Treatment Age|Treatment Type|Treatment Quantity|Treatment Unit|Treatment Application|Treatment Remarks|No of individuals in study|Species|Strain|Sex|Age|Group Endpoints|Individual ID|Group ID|Age at death|Pathology type |Pathology location|Pathology Description|
2-6-1|Rn-Fe-WL 5600,9-2 2/73|1| 77|Rn-222 gas|5600|working level months|Inhalation| inhaled over 3 m at 4800 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study 
|2-6-1-1|1|210|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|,MPATH: 215 - granulomatous inflammation|
2-6-1|Rn-Fe-WL 5600,9-2 2/73|1| 77|Rn-222 gas|5600|working level months|Inhalation| inhaled over 3 m at 4800 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-1-2|1|210|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-6-1|Rn-Fe-WL 5600,9-2 2/73|1| 77|Rn-222 gas|5600|working level months|Inhalation| inhaled over 3 m at 4800 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-1-3|1|254|Hyperplastic changes|Lower respiratory system|n/a|
2-6-1|Rn-Fe-WL 5600,9-2 2/73|1| 77|Rn-222 gas|5600|working level months|Inhalation| inhaled over 3 m at 4800 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-1-4|1|258|Hyperplastic changes|Lower respiratory system|n/a|
2-6-1|Rn-Fe-WL 5600,9-2 2/73|1| 77|Rn-222 gas|5600|working level months|Inhalation| inhaled over 3 m at 4800 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-1-5|1|264|Hyperplastic changes|Lower respiratory system|n/a|
2-6-1|Rn-Fe-WL 5600,9-2 2/73|1| 77|Rn-222 gas|5600|working level months|Inhalation| inhaled over 3 m at 4800 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-1-6|1|270|Hyperplastic changes|Lower respiratory system|n/a|
2-6-1|Rn-Fe-WL 5600,9-2 2/73|1| 77|Rn-222 gas|5600|working level months|Inhalation| inhaled over 3 m at 4800 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-1-7|1|283|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-1|Rn-Fe-WL 5600,9-2 2/73|1| 77|Rn-222 gas|5600|working level months|Inhalation| inhaled over 3 m at 4800 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-1-8|1|287|Neoplasia malignant|Lower respiratory system|n/a|
2-6-1|Rn-Fe-WL 5600,9-2 2/73|1| 77|Rn-222 gas|5600|working level months|Inhalation| inhaled over 3 m at 4800 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-1-9|1|316|Other deterministic changes|Whole body|n/a|
2-6-1|Rn-Fe-WL 5600,9-2 2/73|1| 77|Rn-222 gas|5600|working level months|Inhalation| inhaled over 3 m at 4800 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-1-10|1|349|Other deterministic changes|Whole body|n/a|
2-6-1|Rn-Fe-WL 5600,9-2 2/73|2| 77|Fe-59||unit code not relevant|Injection intrapleural| Intratracheal|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-1-1|1|210|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|,MPATH: 215 - granulomatous inflammation|
2-6-1|Rn-Fe-WL 5600,9-2 2/73|2| 77|Fe-59||unit code not relevant|Injection intrapleural| Intratracheal|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-1-2|1|210|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-6-1|Rn-Fe-WL 5600,9-2 2/73|2| 77|Fe-59||unit code not relevant|Injection intrapleural| Intratracheal|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-1-3|1|254|Hyperplastic changes|Lower respiratory system|n/a|
2-6-1|Rn-Fe-WL 5600,9-2 2/73|2| 77|Fe-59||unit code not relevant|Injection intrapleural| Intratracheal|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-1-4|1|258|Hyperplastic changes|Lower respiratory system|n/a|
2-6-1|Rn-Fe-WL 5600,9-2 2/73|2| 77|Fe-59||unit code not relevant|Injection intrapleural| Intratracheal|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-1-5|1|264|Hyperplastic changes|Lower respiratory system|n/a|
2-6-1|Rn-Fe-WL 5600,9-2 2/73|2| 77|Fe-59||unit code not relevant|Injection intrapleural| Intratracheal|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-1-6|1|270|Hyperplastic changes|Lower respiratory system|n/a|
2-6-1|Rn-Fe-WL 5600,9-2 2/73|2| 77|Fe-59||unit code not relevant|Injection intrapleural| Intratracheal|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-1-7|1|283|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-1|Rn-Fe-WL 5600,9-2 2/73|2| 77|Fe-59||unit code not relevant|Injection intrapleural| Intratracheal|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-1-8|1|287|Neoplasia malignant|Lower respiratory system|n/a|
2-6-1|Rn-Fe-WL 5600,9-2 2/73|2| 77|Fe-59||unit code not relevant|Injection intrapleural| Intratracheal|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-1-9|1|316|Other deterministic changes|Whole body|n/a|
2-6-1|Rn-Fe-WL 5600,9-2 2/73|2| 77|Fe-59||unit code not relevant|Injection intrapleural| Intratracheal|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-1-10|1|349|Other deterministic changes|Whole body|n/a|
2-6-2|Rn-Ce-WL 5600,9-1 2/73|1| 77|Rn-222 gas|5600|working level months|Inhalation| inhaled over 3 m at 4800 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-2-1|2|210|Hyperplastic changes|Lower respiratory system|n/a|
2-6-2|Rn-Ce-WL 5600,9-1 2/73|1| 77|Rn-222 gas|5600|working level months|Inhalation| inhaled over 3 m at 4800 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-2-2|2|216|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-2|Rn-Ce-WL 5600,9-1 2/73|1| 77|Rn-222 gas|5600|working level months|Inhalation| inhaled over 3 m at 4800 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-2-3|2|244|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-2|Rn-Ce-WL 5600,9-1 2/73|1| 77|Rn-222 gas|5600|working level months|Inhalation| inhaled over 3 m at 4800 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-2-4|2|244|Hyperplastic changes|Lower respiratory system|n/a|
2-6-2|Rn-Ce-WL 5600,9-1 2/73|1| 77|Rn-222 gas|5600|working level months|Inhalation| inhaled over 3 m at 4800 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-2-5|2|248|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-2|Rn-Ce-WL 5600,9-1 2/73|1| 77|Rn-222 gas|5600|working level months|Inhalation| inhaled over 3 m at 4800 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-2-6|2|252|Other deterministic changes|Whole body|n/a|
2-6-2|Rn-Ce-WL 5600,9-1 2/73|1| 77|Rn-222 gas|5600|working level months|Inhalation| inhaled over 3 m at 4800 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-2-7|2|253|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-2|Rn-Ce-WL 5600,9-1 2/73|1| 77|Rn-222 gas|5600|working level months|Inhalation| inhaled over 3 m at 4800 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-2-8|2|258|Hyperplastic changes|Lower respiratory system|n/a|
2-6-2|Rn-Ce-WL 5600,9-1 2/73|1| 77|Rn-222 gas|5600|working level months|Inhalation| inhaled over 3 m at 4800 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-2-9|2|264|Other deterministic changes|Whole body|n/a|
2-6-2|Rn-Ce-WL 5600,9-1 2/73|1| 77|Rn-222 gas|5600|working level months|Inhalation| inhaled over 3 m at 4800 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-2-10|2|270|Hyperplastic changes|Lower respiratory system|n/a|
2-6-2|Rn-Ce-WL 5600,9-1 2/73|2| 77|Ce-144 chloride||unit code not relevant|Injection, intramuscular| chemical form unknown IM inject.|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-2-1|2|210|Hyperplastic changes|Lower respiratory system|n/a|
2-6-2|Rn-Ce-WL 5600,9-1 2/73|2| 77|Ce-144 chloride||unit code not relevant|Injection, intramuscular| chemical form unknown IM inject.|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-2-2|2|216|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-2|Rn-Ce-WL 5600,9-1 2/73|2| 77|Ce-144 chloride||unit code not relevant|Injection, intramuscular| chemical form unknown IM inject.|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-2-3|2|244|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-2|Rn-Ce-WL 5600,9-1 2/73|2| 77|Ce-144 chloride||unit code not relevant|Injection, intramuscular| chemical form unknown IM inject.|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-2-4|2|244|Hyperplastic changes|Lower respiratory system|n/a|
2-6-2|Rn-Ce-WL 5600,9-1 2/73|2| 77|Ce-144 chloride||unit code not relevant|Injection, intramuscular| chemical form unknown IM inject.|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-2-5|2|248|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-2|Rn-Ce-WL 5600,9-1 2/73|2| 77|Ce-144 chloride||unit code not relevant|Injection, intramuscular| chemical form unknown IM inject.|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-2-6|2|252|Other deterministic changes|Whole body|n/a|
2-6-2|Rn-Ce-WL 5600,9-1 2/73|2| 77|Ce-144 chloride||unit code not relevant|Injection, intramuscular| chemical form unknown IM inject.|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-2-7|2|253|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-2|Rn-Ce-WL 5600,9-1 2/73|2| 77|Ce-144 chloride||unit code not relevant|Injection, intramuscular| chemical form unknown IM inject.|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-2-8|2|258|Hyperplastic changes|Lower respiratory system|n/a|
2-6-2|Rn-Ce-WL 5600,9-1 2/73|2| 77|Ce-144 chloride||unit code not relevant|Injection, intramuscular| chemical form unknown IM inject.|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-2-9|2|264|Other deterministic changes|Whole body|n/a|
2-6-2|Rn-Ce-WL 5600,9-1 2/73|2| 77|Ce-144 chloride||unit code not relevant|Injection, intramuscular| chemical form unknown IM inject.|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-2-10|2|270|Hyperplastic changes|Lower respiratory system|n/a|
2-6-3|Rn-NE-WL 40,23-2 2/77|1| 77|Rn-222 gas|40|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-1|3|442|Other deterministic changes|Lower respiratory system|n/a|
2-6-3|Rn-NE-WL 40,23-2 2/77|1| 77|Rn-222 gas|40|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-2|3|536|Other deterministic changes|Lower respiratory system|n/a|
2-6-3|Rn-NE-WL 40,23-2 2/77|1| 77|Rn-222 gas|40|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-3|3|576|Other deterministic changes|Whole body|n/a|
2-6-3|Rn-NE-WL 40,23-2 2/77|1| 77|Rn-222 gas|40|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-4|3|578|Other deterministic changes|Whole body|n/a|
2-6-3|Rn-NE-WL 40,23-2 2/77|1| 77|Rn-222 gas|40|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-5|3|611|Other deterministic changes|Lower respiratory system|n/a|
2-6-3|Rn-NE-WL 40,23-2 2/77|1| 77|Rn-222 gas|40|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-6|3|628|Other deterministic changes|Lower respiratory system|n/a|
2-6-3|Rn-NE-WL 40,23-2 2/77|1| 77|Rn-222 gas|40|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-7|3|644|Other deterministic changes|Whole body|n/a|
2-6-3|Rn-NE-WL 40,23-2 2/77|1| 77|Rn-222 gas|40|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-8|3|644|Other deterministic changes|Lower respiratory system|n/a|
2-6-3|Rn-NE-WL 40,23-2 2/77|1| 77|Rn-222 gas|40|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-9|3|704|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 242 - hemangiosarcoma|
2-6-3|Rn-NE-WL 40,23-2 2/77|1| 77|Rn-222 gas|40|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-10|3|708|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-6-3|Rn-NE-WL 40,23-2 2/77|1| 77|Rn-222 gas|40|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-11|3|708|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-6-3|Rn-NE-WL 40,23-2 2/77|1| 77|Rn-222 gas|40|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-12|3|721|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-6-3|Rn-NE-WL 40,23-2 2/77|1| 77|Rn-222 gas|40|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-13|3|721|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 409 - fibrous histiocytoma|
2-6-3|Rn-NE-WL 40,23-2 2/77|1| 77|Rn-222 gas|40|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-14|3|739|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-3|Rn-NE-WL 40,23-2 2/77|1| 77|Rn-222 gas|40|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-15|3|749|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-6-3|Rn-NE-WL 40,23-2 2/77|1| 77|Rn-222 gas|40|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-16|3|762|Neoplasia benign|Lower respiratory system|n/a|
2-6-3|Rn-NE-WL 40,23-2 2/77|2| 27|neutrons fission|3.05|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-1|3|442|Other deterministic changes|Lower respiratory system|n/a|
2-6-3|Rn-NE-WL 40,23-2 2/77|2| 27|neutrons fission|3.05|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-2|3|536|Other deterministic changes|Lower respiratory system|n/a|
2-6-3|Rn-NE-WL 40,23-2 2/77|2| 27|neutrons fission|3.05|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-3|3|576|Other deterministic changes|Whole body|n/a|
2-6-3|Rn-NE-WL 40,23-2 2/77|2| 27|neutrons fission|3.05|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-4|3|578|Other deterministic changes|Whole body|n/a|
2-6-3|Rn-NE-WL 40,23-2 2/77|2| 27|neutrons fission|3.05|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-5|3|611|Other deterministic changes|Lower respiratory system|n/a|
2-6-3|Rn-NE-WL 40,23-2 2/77|2| 27|neutrons fission|3.05|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-6|3|628|Other deterministic changes|Lower respiratory system|n/a|
2-6-3|Rn-NE-WL 40,23-2 2/77|2| 27|neutrons fission|3.05|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-7|3|644|Other deterministic changes|Whole body|n/a|
2-6-3|Rn-NE-WL 40,23-2 2/77|2| 27|neutrons fission|3.05|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-8|3|644|Other deterministic changes|Lower respiratory system|n/a|
2-6-3|Rn-NE-WL 40,23-2 2/77|2| 27|neutrons fission|3.05|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-9|3|704|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 242 - hemangiosarcoma|
2-6-3|Rn-NE-WL 40,23-2 2/77|2| 27|neutrons fission|3.05|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-10|3|708|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-6-3|Rn-NE-WL 40,23-2 2/77|2| 27|neutrons fission|3.05|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-11|3|708|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-6-3|Rn-NE-WL 40,23-2 2/77|2| 27|neutrons fission|3.05|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-12|3|721|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-6-3|Rn-NE-WL 40,23-2 2/77|2| 27|neutrons fission|3.05|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-13|3|721|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 409 - fibrous histiocytoma|
2-6-3|Rn-NE-WL 40,23-2 2/77|2| 27|neutrons fission|3.05|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-14|3|739|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-3|Rn-NE-WL 40,23-2 2/77|2| 27|neutrons fission|3.05|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-15|3|749|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-6-3|Rn-NE-WL 40,23-2 2/77|2| 27|neutrons fission|3.05|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-3-16|3|762|Neoplasia benign|Lower respiratory system|n/a|
2-6-4|Rn-Ne-WL 200,24-2 2/77|1| 77|Rn-222 gas|200|working level months|Inhalation| inhaled at 800 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-1|4|414|Neoplasia systemic|Haematolymphatic system|n/a|
2-6-4|Rn-Ne-WL 200,24-2 2/77|1| 77|Rn-222 gas|200|working level months|Inhalation| inhaled at 800 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-2|4|450|Other deterministic changes|Lower respiratory system|n/a|
2-6-4|Rn-Ne-WL 200,24-2 2/77|1| 77|Rn-222 gas|200|working level months|Inhalation| inhaled at 800 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-3|4|459|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-4|Rn-Ne-WL 200,24-2 2/77|1| 77|Rn-222 gas|200|working level months|Inhalation| inhaled at 800 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-4|4|461|Other deterministic changes|Lower respiratory system|n/a|
2-6-4|Rn-Ne-WL 200,24-2 2/77|1| 77|Rn-222 gas|200|working level months|Inhalation| inhaled at 800 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-5|4|559|Neoplasia malignant|Lower respiratory system|n/a|
2-6-4|Rn-Ne-WL 200,24-2 2/77|1| 77|Rn-222 gas|200|working level months|Inhalation| inhaled at 800 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-6|4|589|Other deterministic changes|Lower respiratory system|n/a|
2-6-4|Rn-Ne-WL 200,24-2 2/77|1| 77|Rn-222 gas|200|working level months|Inhalation| inhaled at 800 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-7|4|604|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 242 - hemangiosarcoma|
2-6-4|Rn-Ne-WL 200,24-2 2/77|1| 77|Rn-222 gas|200|working level months|Inhalation| inhaled at 800 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-8|4|630|Other deterministic changes|Lower respiratory system|n/a|
2-6-4|Rn-Ne-WL 200,24-2 2/77|1| 77|Rn-222 gas|200|working level months|Inhalation| inhaled at 800 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-9|4|631|Other deterministic changes|Lower respiratory system|n/a|
2-6-4|Rn-Ne-WL 200,24-2 2/77|1| 77|Rn-222 gas|200|working level months|Inhalation| inhaled at 800 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-10|4|636|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-4|Rn-Ne-WL 200,24-2 2/77|1| 77|Rn-222 gas|200|working level months|Inhalation| inhaled at 800 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-11|4|639|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-4|Rn-Ne-WL 200,24-2 2/77|1| 77|Rn-222 gas|200|working level months|Inhalation| inhaled at 800 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-12|4|639|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-4|Rn-Ne-WL 200,24-2 2/77|1| 77|Rn-222 gas|200|working level months|Inhalation| inhaled at 800 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-13|4|639|Neoplasia malignant|Lower respiratory system|n/a|
2-6-4|Rn-Ne-WL 200,24-2 2/77|1| 77|Rn-222 gas|200|working level months|Inhalation| inhaled at 800 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-14|4|659|Neoplasia malignant|Lower respiratory system|n/a|
2-6-4|Rn-Ne-WL 200,24-2 2/77|1| 77|Rn-222 gas|200|working level months|Inhalation| inhaled at 800 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-15|4|681|Neoplasia benign|Lower respiratory system|n/a|
2-6-4|Rn-Ne-WL 200,24-2 2/77|1| 77|Rn-222 gas|200|working level months|Inhalation| inhaled at 800 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-16|4|699|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-4|Rn-Ne-WL 200,24-2 2/77|2| 22|neutrons fission|2.14|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-1|4|414|Neoplasia systemic|Haematolymphatic system|n/a|
2-6-4|Rn-Ne-WL 200,24-2 2/77|2| 22|neutrons fission|2.14|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-2|4|450|Other deterministic changes|Lower respiratory system|n/a|
2-6-4|Rn-Ne-WL 200,24-2 2/77|2| 22|neutrons fission|2.14|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-3|4|459|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-4|Rn-Ne-WL 200,24-2 2/77|2| 22|neutrons fission|2.14|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-4|4|461|Other deterministic changes|Lower respiratory system|n/a|
2-6-4|Rn-Ne-WL 200,24-2 2/77|2| 22|neutrons fission|2.14|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-5|4|559|Neoplasia malignant|Lower respiratory system|n/a|
2-6-4|Rn-Ne-WL 200,24-2 2/77|2| 22|neutrons fission|2.14|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-6|4|589|Other deterministic changes|Lower respiratory system|n/a|
2-6-4|Rn-Ne-WL 200,24-2 2/77|2| 22|neutrons fission|2.14|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-7|4|604|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 242 - hemangiosarcoma|
2-6-4|Rn-Ne-WL 200,24-2 2/77|2| 22|neutrons fission|2.14|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-8|4|630|Other deterministic changes|Lower respiratory system|n/a|
2-6-4|Rn-Ne-WL 200,24-2 2/77|2| 22|neutrons fission|2.14|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-9|4|631|Other deterministic changes|Lower respiratory system|n/a|
2-6-4|Rn-Ne-WL 200,24-2 2/77|2| 22|neutrons fission|2.14|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-10|4|636|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-4|Rn-Ne-WL 200,24-2 2/77|2| 22|neutrons fission|2.14|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-11|4|639|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-4|Rn-Ne-WL 200,24-2 2/77|2| 22|neutrons fission|2.14|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-12|4|639|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-4|Rn-Ne-WL 200,24-2 2/77|2| 22|neutrons fission|2.14|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-13|4|639|Neoplasia malignant|Lower respiratory system|n/a|
2-6-4|Rn-Ne-WL 200,24-2 2/77|2| 22|neutrons fission|2.14|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-14|4|659|Neoplasia malignant|Lower respiratory system|n/a|
2-6-4|Rn-Ne-WL 200,24-2 2/77|2| 22|neutrons fission|2.14|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-15|4|681|Neoplasia benign|Lower respiratory system|n/a|
2-6-4|Rn-Ne-WL 200,24-2 2/77|2| 22|neutrons fission|2.14|grays|External exposure| whole body|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-4-16|4|699|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-5|Rn-BY-WL 2240,38-6 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-1|5|423|Other deterministic changes|Lower respiratory system|n/a|
2-6-5|Rn-BY-WL 2240,38-6 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-2|5|489|Neoplasia malignant|Bone among musculo-skeletal system diseases| metastatic|
2-6-5|Rn-BY-WL 2240,38-6 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-3|5|626|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-6-5|Rn-BY-WL 2240,38-6 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-4|5|637|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-6-5|Rn-BY-WL 2240,38-6 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-5|5|668|Neoplasia malignant|Lower respiratory system|n/a|
2-6-5|Rn-BY-WL 2240,38-6 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-6|5|694|Neoplasia malignant|Lower respiratory system|n/a|
2-6-5|Rn-BY-WL 2240,38-6 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-7|5|714|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-6-5|Rn-BY-WL 2240,38-6 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-8|5|715|Neoplasia benign|Lower respiratory system|n/a|
2-6-5|Rn-BY-WL 2240,38-6 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-9|5|770|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 219 - adnexal and skin appendage tumor|
2-6-5|Rn-BY-WL 2240,38-6 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-10|5|798|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-6-5|Rn-BY-WL 2240,38-6 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-11|5|812|Neoplasia malignant|Lower respiratory system|n/a|
2-6-5|Rn-BY-WL 2240,38-6 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-12|5|812|Neoplasia malignant|Lower respiratory system|n/a|
2-6-5|Rn-BY-WL 2240,38-6 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-13|5|857|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-5|Rn-BY-WL 2240,38-6 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-14|5|876|Neoplasia malignant|Lower respiratory system|n/a|
2-6-5|Rn-BY-WL 2240,38-6 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-15|5|916|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-6-5|Rn-BY-WL 2240,38-6 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-16|5|916|Neoplasia benign|Lower respiratory system|n/a|
2-6-5|Rn-BY-WL 2240,38-6 4/79|2| 67|butter yellow||unit code not relevant|Ingestion in food or water| oral continuous for 190 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-1|5|423|Other deterministic changes|Lower respiratory system|n/a|
2-6-5|Rn-BY-WL 2240,38-6 4/79|2| 67|butter yellow||unit code not relevant|Ingestion in food or water| oral continuous for 190 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-2|5|489|Neoplasia malignant|Bone among musculo-skeletal system diseases| metastatic|
2-6-5|Rn-BY-WL 2240,38-6 4/79|2| 67|butter yellow||unit code not relevant|Ingestion in food or water| oral continuous for 190 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-3|5|626|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-6-5|Rn-BY-WL 2240,38-6 4/79|2| 67|butter yellow||unit code not relevant|Ingestion in food or water| oral continuous for 190 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-4|5|637|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-6-5|Rn-BY-WL 2240,38-6 4/79|2| 67|butter yellow||unit code not relevant|Ingestion in food or water| oral continuous for 190 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-5|5|668|Neoplasia malignant|Lower respiratory system|n/a|
2-6-5|Rn-BY-WL 2240,38-6 4/79|2| 67|butter yellow||unit code not relevant|Ingestion in food or water| oral continuous for 190 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-6|5|694|Neoplasia malignant|Lower respiratory system|n/a|
2-6-5|Rn-BY-WL 2240,38-6 4/79|2| 67|butter yellow||unit code not relevant|Ingestion in food or water| oral continuous for 190 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-7|5|714|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-6-5|Rn-BY-WL 2240,38-6 4/79|2| 67|butter yellow||unit code not relevant|Ingestion in food or water| oral continuous for 190 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-8|5|715|Neoplasia benign|Lower respiratory system|n/a|
2-6-5|Rn-BY-WL 2240,38-6 4/79|2| 67|butter yellow||unit code not relevant|Ingestion in food or water| oral continuous for 190 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-9|5|770|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 219 - adnexal and skin appendage tumor|
2-6-5|Rn-BY-WL 2240,38-6 4/79|2| 67|butter yellow||unit code not relevant|Ingestion in food or water| oral continuous for 190 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-10|5|798|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-6-5|Rn-BY-WL 2240,38-6 4/79|2| 67|butter yellow||unit code not relevant|Ingestion in food or water| oral continuous for 190 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-11|5|812|Neoplasia malignant|Lower respiratory system|n/a|
2-6-5|Rn-BY-WL 2240,38-6 4/79|2| 67|butter yellow||unit code not relevant|Ingestion in food or water| oral continuous for 190 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-12|5|812|Neoplasia malignant|Lower respiratory system|n/a|
2-6-5|Rn-BY-WL 2240,38-6 4/79|2| 67|butter yellow||unit code not relevant|Ingestion in food or water| oral continuous for 190 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-13|5|857|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-5|Rn-BY-WL 2240,38-6 4/79|2| 67|butter yellow||unit code not relevant|Ingestion in food or water| oral continuous for 190 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-14|5|876|Neoplasia malignant|Lower respiratory system|n/a|
2-6-5|Rn-BY-WL 2240,38-6 4/79|2| 67|butter yellow||unit code not relevant|Ingestion in food or water| oral continuous for 190 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-15|5|916|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-6-5|Rn-BY-WL 2240,38-6 4/79|2| 67|butter yellow||unit code not relevant|Ingestion in food or water| oral continuous for 190 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-5-16|5|916|Neoplasia benign|Lower respiratory system|n/a|
2-6-6|Rn-ME-WL 0,20/-6 1/76|1| 153|Rn-222 gas|0|working level months|Inhalation| n/a|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-6-1|6|688|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-6-6|Rn-ME-WL 0,20/-6 1/76|1| 153|Rn-222 gas|0|working level months|Inhalation| n/a|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-6-2|6|728|Other deterministic changes|Whole body|n/a|
2-6-6|Rn-ME-WL 0,20/-6 1/76|1| 153|Rn-222 gas|0|working level months|Inhalation| n/a|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-6-3|6|738|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-6-6|Rn-ME-WL 0,20/-6 1/76|1| 153|Rn-222 gas|0|working level months|Inhalation| n/a|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-6-4|6|753|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-6-6|Rn-ME-WL 0,20/-6 1/76|1| 153|Rn-222 gas|0|working level months|Inhalation| n/a|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-6-5|6|755|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
2-6-6|Rn-ME-WL 0,20/-6 1/76|1| 153|Rn-222 gas|0|working level months|Inhalation| n/a|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-6-6|6|755|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas| benign,MPATH: 268 - adenocarcinoma|
2-6-6|Rn-ME-WL 0,20/-6 1/76|1| 153|Rn-222 gas|0|working level months|Inhalation| n/a|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-6-7|6|471|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
2-6-6|Rn-ME-WL 0,20/-6 1/76|1| 153|Rn-222 gas|0|working level months|Inhalation| n/a|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-6-8|6|474|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
2-6-6|Rn-ME-WL 0,20/-6 1/76|1| 153|Rn-222 gas|0|working level months|Inhalation| n/a|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-6-9|6|487|Other deterministic changes|Lower respiratory system|n/a|
2-6-6|Rn-ME-WL 0,20/-6 1/76|1| 153|Rn-222 gas|0|working level months|Inhalation| n/a|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-6-10|6|489|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
2-6-6|Rn-ME-WL 0,20/-6 1/76|1| 153|Rn-222 gas|0|working level months|Inhalation| n/a|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-6-11|6|489|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
2-6-6|Rn-ME-WL 0,20/-6 1/76|1| 153|Rn-222 gas|0|working level months|Inhalation| n/a|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-6-12|6|489|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
2-6-6|Rn-ME-WL 0,20/-6 1/76|2| 508|methylcholanthrene|25|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject. 100d|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-6-1|6|688|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-6-6|Rn-ME-WL 0,20/-6 1/76|2| 508|methylcholanthrene|25|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject. 100d|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-6-2|6|728|Other deterministic changes|Whole body|n/a|
2-6-6|Rn-ME-WL 0,20/-6 1/76|2| 508|methylcholanthrene|25|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject. 100d|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-6-3|6|738|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-6-6|Rn-ME-WL 0,20/-6 1/76|2| 508|methylcholanthrene|25|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject. 100d|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-6-4|6|753|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-6-6|Rn-ME-WL 0,20/-6 1/76|2| 508|methylcholanthrene|25|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject. 100d|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-6-5|6|755|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
2-6-6|Rn-ME-WL 0,20/-6 1/76|2| 508|methylcholanthrene|25|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject. 100d|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-6-6|6|755|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas| benign,MPATH: 268 - adenocarcinoma|
2-6-6|Rn-ME-WL 0,20/-6 1/76|2| 508|methylcholanthrene|25|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject. 100d|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-6-7|6|471|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
2-6-6|Rn-ME-WL 0,20/-6 1/76|2| 508|methylcholanthrene|25|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject. 100d|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-6-8|6|474|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
2-6-6|Rn-ME-WL 0,20/-6 1/76|2| 508|methylcholanthrene|25|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject. 100d|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-6-9|6|487|Other deterministic changes|Lower respiratory system|n/a|
2-6-6|Rn-ME-WL 0,20/-6 1/76|2| 508|methylcholanthrene|25|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject. 100d|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-6-10|6|489|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
2-6-6|Rn-ME-WL 0,20/-6 1/76|2| 508|methylcholanthrene|25|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject. 100d|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-6-11|6|489|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
2-6-6|Rn-ME-WL 0,20/-6 1/76|2| 508|methylcholanthrene|25|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject. 100d|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-6-12|6|489|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
2-6-7|Rn-ME-WL 2100,20-7 1/76|1| 365|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-7-1|7|586|Neoplasia benign|Lower respiratory system|n/a|
2-6-7|Rn-ME-WL 2100,20-7 1/76|1| 365|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-7-2|7|612|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
2-6-7|Rn-ME-WL 2100,20-7 1/76|1| 365|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-7-3|7|619|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-7|Rn-ME-WL 2100,20-7 1/76|1| 365|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-7-4|7|638|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-6-7|Rn-ME-WL 2100,20-7 1/76|1| 365|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-7-5|7|642|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
2-6-7|Rn-ME-WL 2100,20-7 1/76|1| 365|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-7-6|7|667|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-6-7|Rn-ME-WL 2100,20-7 1/76|2| 730|methylcholanthrene|25|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-7-1|7|586|Neoplasia benign|Lower respiratory system|n/a|
2-6-7|Rn-ME-WL 2100,20-7 1/76|2| 730|methylcholanthrene|25|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-7-2|7|612|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
2-6-7|Rn-ME-WL 2100,20-7 1/76|2| 730|methylcholanthrene|25|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-7-3|7|619|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-7|Rn-ME-WL 2100,20-7 1/76|2| 730|methylcholanthrene|25|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-7-4|7|638|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-6-7|Rn-ME-WL 2100,20-7 1/76|2| 730|methylcholanthrene|25|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-7-5|7|642|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
2-6-7|Rn-ME-WL 2100,20-7 1/76|2| 730|methylcholanthrene|25|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-7-6|7|667|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-6-8|Rn-FU-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-1|8|202|Other deterministic changes|Whole body|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-2|8|211|Other deterministic changes|Whole body|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-3|8|223|Other deterministic changes|Whole body|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-4|8|248|Other deterministic changes|Whole body|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-5|8|256|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-6|8|280|Other deterministic changes|Whole body|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-7|8|325|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-8|8|390|Other deterministic changes|Whole body|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-9|8|395|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-10|8|430|Other deterministic changes|Whole body|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-11|8|436|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-6-8|Rn-FU-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-12|8|441|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-13|8|469|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-14|8|544|Hyperplastic changes|Lower respiratory system|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-15|8|551|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-6-8|Rn-FU-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-16|8|555|Neoplasia malignant|Upper respiratory system,MA: 0000442 - upper respiratory tract|,MPATH: 218 - neoplasm|
2-6-8|Rn-FU-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-17|8|557|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-18|8|560|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-6-8|Rn-FU-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-19|8|571|Hyperplastic changes|Lower respiratory system|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-20|8|588|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-6-8|Rn-FU-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-21|8|590|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-8|Rn-FU-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-22|8|613|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-6-8|Rn-FU-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-23|8|622|Neoplasia benign|Lower respiratory system|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-24|8|628|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-8|Rn-FU-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-25|8|653|Hyperplastic changes|Lower respiratory system|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-26|8|718|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-8|Rn-FU-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-27|8|724|Neoplasia malignant|Lower respiratory system|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-28|8|754|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-6-8|Rn-FU-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-29|8|754|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-8|Rn-FU-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-30|8|754|Neoplasia benign|Lower respiratory system|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|2| 78|5-fluorouracil||unit code not relevant|Injection, intraperitoneal| 1/w IP inject.following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-1|8|202|Other deterministic changes|Whole body|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|2| 78|5-fluorouracil||unit code not relevant|Injection, intraperitoneal| 1/w IP inject.following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-2|8|211|Other deterministic changes|Whole body|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|2| 78|5-fluorouracil||unit code not relevant|Injection, intraperitoneal| 1/w IP inject.following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-3|8|223|Other deterministic changes|Whole body|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|2| 78|5-fluorouracil||unit code not relevant|Injection, intraperitoneal| 1/w IP inject.following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-4|8|248|Other deterministic changes|Whole body|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|2| 78|5-fluorouracil||unit code not relevant|Injection, intraperitoneal| 1/w IP inject.following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-5|8|256|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|2| 78|5-fluorouracil||unit code not relevant|Injection, intraperitoneal| 1/w IP inject.following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-6|8|280|Other deterministic changes|Whole body|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|2| 78|5-fluorouracil||unit code not relevant|Injection, intraperitoneal| 1/w IP inject.following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-7|8|325|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|2| 78|5-fluorouracil||unit code not relevant|Injection, intraperitoneal| 1/w IP inject.following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-8|8|390|Other deterministic changes|Whole body|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|2| 78|5-fluorouracil||unit code not relevant|Injection, intraperitoneal| 1/w IP inject.following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-9|8|395|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|2| 78|5-fluorouracil||unit code not relevant|Injection, intraperitoneal| 1/w IP inject.following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-10|8|430|Other deterministic changes|Whole body|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|2| 78|5-fluorouracil||unit code not relevant|Injection, intraperitoneal| 1/w IP inject.following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-11|8|436|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-6-8|Rn-FU-WL 2100,12 11/73|2| 78|5-fluorouracil||unit code not relevant|Injection, intraperitoneal| 1/w IP inject.following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-12|8|441|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|2| 78|5-fluorouracil||unit code not relevant|Injection, intraperitoneal| 1/w IP inject.following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-13|8|469|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|2| 78|5-fluorouracil||unit code not relevant|Injection, intraperitoneal| 1/w IP inject.following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-14|8|544|Hyperplastic changes|Lower respiratory system|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|2| 78|5-fluorouracil||unit code not relevant|Injection, intraperitoneal| 1/w IP inject.following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-15|8|551|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-6-8|Rn-FU-WL 2100,12 11/73|2| 78|5-fluorouracil||unit code not relevant|Injection, intraperitoneal| 1/w IP inject.following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-16|8|555|Neoplasia malignant|Upper respiratory system,MA: 0000442 - upper respiratory tract|,MPATH: 218 - neoplasm|
2-6-8|Rn-FU-WL 2100,12 11/73|2| 78|5-fluorouracil||unit code not relevant|Injection, intraperitoneal| 1/w IP inject.following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-17|8|557|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|2| 78|5-fluorouracil||unit code not relevant|Injection, intraperitoneal| 1/w IP inject.following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-18|8|560|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-6-8|Rn-FU-WL 2100,12 11/73|2| 78|5-fluorouracil||unit code not relevant|Injection, intraperitoneal| 1/w IP inject.following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-19|8|571|Hyperplastic changes|Lower respiratory system|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|2| 78|5-fluorouracil||unit code not relevant|Injection, intraperitoneal| 1/w IP inject.following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-20|8|588|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-6-8|Rn-FU-WL 2100,12 11/73|2| 78|5-fluorouracil||unit code not relevant|Injection, intraperitoneal| 1/w IP inject.following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-21|8|590|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-8|Rn-FU-WL 2100,12 11/73|2| 78|5-fluorouracil||unit code not relevant|Injection, intraperitoneal| 1/w IP inject.following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-22|8|613|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-6-8|Rn-FU-WL 2100,12 11/73|2| 78|5-fluorouracil||unit code not relevant|Injection, intraperitoneal| 1/w IP inject.following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-23|8|622|Neoplasia benign|Lower respiratory system|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|2| 78|5-fluorouracil||unit code not relevant|Injection, intraperitoneal| 1/w IP inject.following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-24|8|628|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-8|Rn-FU-WL 2100,12 11/73|2| 78|5-fluorouracil||unit code not relevant|Injection, intraperitoneal| 1/w IP inject.following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-25|8|653|Hyperplastic changes|Lower respiratory system|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|2| 78|5-fluorouracil||unit code not relevant|Injection, intraperitoneal| 1/w IP inject.following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-26|8|718|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-8|Rn-FU-WL 2100,12 11/73|2| 78|5-fluorouracil||unit code not relevant|Injection, intraperitoneal| 1/w IP inject.following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-27|8|724|Neoplasia malignant|Lower respiratory system|n/a|
2-6-8|Rn-FU-WL 2100,12 11/73|2| 78|5-fluorouracil||unit code not relevant|Injection, intraperitoneal| 1/w IP inject.following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-28|8|754|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-6-8|Rn-FU-WL 2100,12 11/73|2| 78|5-fluorouracil||unit code not relevant|Injection, intraperitoneal| 1/w IP inject.following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-29|8|754|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-8|Rn-FU-WL 2100,12 11/73|2| 78|5-fluorouracil||unit code not relevant|Injection, intraperitoneal| 1/w IP inject.following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-8-30|8|754|Neoplasia benign|Lower respiratory system|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-1|9|61|Other deterministic changes|Whole body|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-2|9|256|Other deterministic changes|Lower respiratory system|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-3|9|268|Other deterministic changes|Whole body|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-4|9|273|Other deterministic changes|Whole body|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-5|9|308|Other deterministic changes|Whole body|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-6|9|341|Other deterministic changes|Whole body|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-7|9|389|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-8|9|409|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-9|9|413|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-10|9|418|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-6-9|Rn-EN-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-11|9|424|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-12|9|445|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-13|9|446|Other deterministic changes|Whole body|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-14|9|451|Hyperplastic changes|Lower respiratory system|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-15|9|455|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-16|9|486|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-17|9|500|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-6-9|Rn-EN-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-18|9|522|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-19|9|541|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-20|9|545|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-21|9|557|Hyperplastic changes|Lower respiratory system|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-22|9|564|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-6-9|Rn-EN-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-23|9|571|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-9|Rn-EN-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-24|9|578|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-25|9|585|Neoplasia malignant|Lower respiratory system|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-26|9|648|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-9|Rn-EN-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-27|9|677|Hyperplastic changes|Lower respiratory system|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-28|9|685|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-9|Rn-EN-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-29|9|685|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-9|Rn-EN-WL 2100,12 11/73|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-30|9|706|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-9|Rn-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-1|9|61|Other deterministic changes|Whole body|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-2|9|256|Other deterministic changes|Lower respiratory system|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-3|9|268|Other deterministic changes|Whole body|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-4|9|273|Other deterministic changes|Whole body|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-5|9|308|Other deterministic changes|Whole body|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-6|9|341|Other deterministic changes|Whole body|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-7|9|389|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-8|9|409|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-9|9|413|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-10|9|418|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-6-9|Rn-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-11|9|424|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-12|9|445|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-13|9|446|Other deterministic changes|Whole body|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-14|9|451|Hyperplastic changes|Lower respiratory system|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-15|9|455|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-16|9|486|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-17|9|500|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-6-9|Rn-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-18|9|522|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-19|9|541|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-20|9|545|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-21|9|557|Hyperplastic changes|Lower respiratory system|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-22|9|564|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-6-9|Rn-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-23|9|571|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-9|Rn-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-24|9|578|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-25|9|585|Neoplasia malignant|Lower respiratory system|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-26|9|648|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-9|Rn-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-27|9|677|Hyperplastic changes|Lower respiratory system|n/a|
2-6-9|Rn-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-28|9|685|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-9|Rn-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-29|9|685|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-9|Rn-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-9-30|9|706|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-10|Rn*-EN-WL 2100,12 11/73|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-1|10|435|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-2|10|623|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-3|10|635|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-4|10|639|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-5|10|640|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-6|10|640|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-7|10|642|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-6-10|Rn*-EN-WL 2100,12 11/73|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-8|10|642|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-9|10|642|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-10|10|642|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-11|10|645|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-12|10|670|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-13|10|702|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-14|10|705|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-10|Rn*-EN-WL 2100,12 11/73|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-15|10|729|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-16|10|744|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-17|10|744|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-10|Rn*-EN-WL 2100,12 11/73|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-18|10|745|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-6-10|Rn*-EN-WL 2100,12 11/73|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-19|10|759|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-10|Rn*-EN-WL 2100,12 11/73|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-20|10|780|Other deterministic changes|Whole body|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-21|10|796|Neoplasia malignant|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-22|10|799|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 549 - carcinoma|
2-6-10|Rn*-EN-WL 2100,12 11/73|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-23|10|799|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-6-10|Rn*-EN-WL 2100,12 11/73|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-24|10|807|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-6-10|Rn*-EN-WL 2100,12 11/73|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-25|10|814|Neoplasia malignant|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-26|10|815|Hyperplastic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-27|10|858|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-6-10|Rn*-EN-WL 2100,12 11/73|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-28|10|864|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-29|10|901|Neoplasia malignant|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-30|10|923|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-1|10|435|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-2|10|623|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-3|10|635|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-4|10|639|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-5|10|640|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-6|10|640|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-7|10|642|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-6-10|Rn*-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-8|10|642|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-9|10|642|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-10|10|642|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-11|10|645|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-12|10|670|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-13|10|702|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-14|10|705|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-10|Rn*-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-15|10|729|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-16|10|744|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-17|10|744|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-10|Rn*-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-18|10|745|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-6-10|Rn*-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-19|10|759|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-10|Rn*-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-20|10|780|Other deterministic changes|Whole body|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-21|10|796|Neoplasia malignant|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-22|10|799|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 549 - carcinoma|
2-6-10|Rn*-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-23|10|799|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-6-10|Rn*-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-24|10|807|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-6-10|Rn*-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-25|10|814|Neoplasia malignant|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-26|10|815|Hyperplastic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-27|10|858|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-6-10|Rn*-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-28|10|864|Other deterministic changes|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-29|10|901|Neoplasia malignant|Lower respiratory system|n/a|
2-6-10|Rn*-EN-WL 2100,12 11/73|2| 78|endoxane|50|milligrams per kg animal|Injection, intraperitoneal| 1/w IP inject.3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-10-30|10|923|Other deterministic changes|Lower respiratory system|n/a|
2-6-11|Rn-BL-WL 2100,18-3 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-1|11|214|Other deterministic changes|Whole body|n/a|
2-6-11|Rn-BL-WL 2100,18-3 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-2|11|217|Other deterministic changes|Whole body|n/a|
2-6-11|Rn-BL-WL 2100,18-3 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-3|11|270|Other deterministic changes|Whole body|n/a|
2-6-11|Rn-BL-WL 2100,18-3 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-4|11|316|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-11|Rn-BL-WL 2100,18-3 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-5|11|367|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-11|Rn-BL-WL 2100,18-3 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-6|11|393|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-11|Rn-BL-WL 2100,18-3 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-7|11|419|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-11|Rn-BL-WL 2100,18-3 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-8|11|427|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-11|Rn-BL-WL 2100,18-3 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-9|11|437|Other deterministic changes|Whole body|n/a|
2-6-11|Rn-BL-WL 2100,18-3 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-10|11|455|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-11|Rn-BL-WL 2100,18-3 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-11|11|462|Other deterministic changes|Whole body|n/a|
2-6-11|Rn-BL-WL 2100,18-3 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-12|11|548|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-6-11|Rn-BL-WL 2100,18-3 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-13|11|563|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-11|Rn-BL-WL 2100,18-3 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-14|11|579|Neoplasia malignant|Upper respiratory system,MA: 0000442 - upper respiratory tract|,MPATH: 218 - neoplasm|
2-6-11|Rn-BL-WL 2100,18-3 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-15|11|595|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-11|Rn-BL-WL 2100,18-3 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-16|11|605|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-11|Rn-BL-WL 2100,18-3 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-17|11|620|Hyperplastic changes|Lower respiratory system|n/a|
2-6-11|Rn-BL-WL 2100,18-3 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-18|11|622|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-6-11|Rn-BL-WL 2100,18-3 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-19|11|632|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 549 - carcinoma|
2-6-11|Rn-BL-WL 2100,18-3 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-20|11|641|Hyperplastic changes|Lower respiratory system|n/a|
2-6-11|Rn-BL-WL 2100,18-3 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-21|11|655|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-11|Rn-BL-WL 2100,18-3 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-22|11|657|Hyperplastic changes|Lower respiratory system|n/a|
2-6-11|Rn-BL-WL 2100,18-3 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-23|11|661|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-6-11|Rn-BL-WL 2100,18-3 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-24|11|674|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-11|Rn-BL-WL 2100,18-3 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-25|11|690|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-11|Rn-BL-WL 2100,18-3 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-26|11|691|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-6-11|Rn-BL-WL 2100,18-3 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-27|11|695|Hyperplastic changes|Lower respiratory system|n/a|
2-6-11|Rn-BL-WL 2100,18-3 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-28|11|695|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-11|Rn-BL-WL 2100,18-3 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-29|11|746|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-11|Rn-BL-WL 2100,18-3 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 1 m at 3600 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-30|11|748|Hyperplastic changes|Lower respiratory system|n/a|
2-6-11|Rn-BL-WL 2100,18-3 1/76|2| 522|bleomycine|10|micrograms|Injection, intraperitoneal| 1/w IP inject. 3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-1|11|214|Other deterministic changes|Whole body|n/a|
2-6-11|Rn-BL-WL 2100,18-3 1/76|2| 522|bleomycine|10|micrograms|Injection, intraperitoneal| 1/w IP inject. 3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-2|11|217|Other deterministic changes|Whole body|n/a|
2-6-11|Rn-BL-WL 2100,18-3 1/76|2| 522|bleomycine|10|micrograms|Injection, intraperitoneal| 1/w IP inject. 3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-3|11|270|Other deterministic changes|Whole body|n/a|
2-6-11|Rn-BL-WL 2100,18-3 1/76|2| 522|bleomycine|10|micrograms|Injection, intraperitoneal| 1/w IP inject. 3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-4|11|316|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-11|Rn-BL-WL 2100,18-3 1/76|2| 522|bleomycine|10|micrograms|Injection, intraperitoneal| 1/w IP inject. 3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-5|11|367|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-11|Rn-BL-WL 2100,18-3 1/76|2| 522|bleomycine|10|micrograms|Injection, intraperitoneal| 1/w IP inject. 3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-6|11|393|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-11|Rn-BL-WL 2100,18-3 1/76|2| 522|bleomycine|10|micrograms|Injection, intraperitoneal| 1/w IP inject. 3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-7|11|419|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-11|Rn-BL-WL 2100,18-3 1/76|2| 522|bleomycine|10|micrograms|Injection, intraperitoneal| 1/w IP inject. 3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-8|11|427|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-11|Rn-BL-WL 2100,18-3 1/76|2| 522|bleomycine|10|micrograms|Injection, intraperitoneal| 1/w IP inject. 3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-9|11|437|Other deterministic changes|Whole body|n/a|
2-6-11|Rn-BL-WL 2100,18-3 1/76|2| 522|bleomycine|10|micrograms|Injection, intraperitoneal| 1/w IP inject. 3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-10|11|455|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-11|Rn-BL-WL 2100,18-3 1/76|2| 522|bleomycine|10|micrograms|Injection, intraperitoneal| 1/w IP inject. 3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-11|11|462|Other deterministic changes|Whole body|n/a|
2-6-11|Rn-BL-WL 2100,18-3 1/76|2| 522|bleomycine|10|micrograms|Injection, intraperitoneal| 1/w IP inject. 3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-12|11|548|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-6-11|Rn-BL-WL 2100,18-3 1/76|2| 522|bleomycine|10|micrograms|Injection, intraperitoneal| 1/w IP inject. 3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-13|11|563|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-11|Rn-BL-WL 2100,18-3 1/76|2| 522|bleomycine|10|micrograms|Injection, intraperitoneal| 1/w IP inject. 3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-14|11|579|Neoplasia malignant|Upper respiratory system,MA: 0000442 - upper respiratory tract|,MPATH: 218 - neoplasm|
2-6-11|Rn-BL-WL 2100,18-3 1/76|2| 522|bleomycine|10|micrograms|Injection, intraperitoneal| 1/w IP inject. 3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-15|11|595|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-11|Rn-BL-WL 2100,18-3 1/76|2| 522|bleomycine|10|micrograms|Injection, intraperitoneal| 1/w IP inject. 3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-16|11|605|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-11|Rn-BL-WL 2100,18-3 1/76|2| 522|bleomycine|10|micrograms|Injection, intraperitoneal| 1/w IP inject. 3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-17|11|620|Hyperplastic changes|Lower respiratory system|n/a|
2-6-11|Rn-BL-WL 2100,18-3 1/76|2| 522|bleomycine|10|micrograms|Injection, intraperitoneal| 1/w IP inject. 3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-18|11|622|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-6-11|Rn-BL-WL 2100,18-3 1/76|2| 522|bleomycine|10|micrograms|Injection, intraperitoneal| 1/w IP inject. 3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-19|11|632|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 549 - carcinoma|
2-6-11|Rn-BL-WL 2100,18-3 1/76|2| 522|bleomycine|10|micrograms|Injection, intraperitoneal| 1/w IP inject. 3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-20|11|641|Hyperplastic changes|Lower respiratory system|n/a|
2-6-11|Rn-BL-WL 2100,18-3 1/76|2| 522|bleomycine|10|micrograms|Injection, intraperitoneal| 1/w IP inject. 3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-21|11|655|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-11|Rn-BL-WL 2100,18-3 1/76|2| 522|bleomycine|10|micrograms|Injection, intraperitoneal| 1/w IP inject. 3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-22|11|657|Hyperplastic changes|Lower respiratory system|n/a|
2-6-11|Rn-BL-WL 2100,18-3 1/76|2| 522|bleomycine|10|micrograms|Injection, intraperitoneal| 1/w IP inject. 3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-23|11|661|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-6-11|Rn-BL-WL 2100,18-3 1/76|2| 522|bleomycine|10|micrograms|Injection, intraperitoneal| 1/w IP inject. 3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-24|11|674|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-11|Rn-BL-WL 2100,18-3 1/76|2| 522|bleomycine|10|micrograms|Injection, intraperitoneal| 1/w IP inject. 3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-25|11|690|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-11|Rn-BL-WL 2100,18-3 1/76|2| 522|bleomycine|10|micrograms|Injection, intraperitoneal| 1/w IP inject. 3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-26|11|691|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-6-11|Rn-BL-WL 2100,18-3 1/76|2| 522|bleomycine|10|micrograms|Injection, intraperitoneal| 1/w IP inject. 3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-27|11|695|Hyperplastic changes|Lower respiratory system|n/a|
2-6-11|Rn-BL-WL 2100,18-3 1/76|2| 522|bleomycine|10|micrograms|Injection, intraperitoneal| 1/w IP inject. 3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-28|11|695|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-11|Rn-BL-WL 2100,18-3 1/76|2| 522|bleomycine|10|micrograms|Injection, intraperitoneal| 1/w IP inject. 3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-29|11|746|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-11|Rn-BL-WL 2100,18-3 1/76|2| 522|bleomycine|10|micrograms|Injection, intraperitoneal| 1/w IP inject. 3 doses following European standard protocol scaled for rats|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-11-30|11|748|Hyperplastic changes|Lower respiratory system|n/a|
2-6-12|Rn-LA-WL 1960,34-1 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-1|12|399|Neoplasia systemic|Haematolymphatic system|n/a|
2-6-12|Rn-LA-WL 1960,34-1 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-2|12|496|Other deterministic changes|Lower respiratory system|n/a|
2-6-12|Rn-LA-WL 1960,34-1 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-3|12|527|Neoplasia malignant|Lower respiratory system|n/a|
2-6-12|Rn-LA-WL 1960,34-1 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-4|12|629|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-12|Rn-LA-WL 1960,34-1 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-5|12|685|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-6-12|Rn-LA-WL 1960,34-1 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-6|12|714|Other deterministic changes|Lower respiratory system|n/a|
2-6-12|Rn-LA-WL 1960,34-1 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-7|12|732|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|,MPATH: 215 - granulomatous inflammation|
2-6-12|Rn-LA-WL 1960,34-1 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-8|12|743|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland| metastatic,MPATH: 268 - adenocarcinoma|
2-6-12|Rn-LA-WL 1960,34-1 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-9|12|751|Neoplasia benign|Lower respiratory system|n/a|
2-6-12|Rn-LA-WL 1960,34-1 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-10|12|768|Other deterministic changes|Lower respiratory system|n/a|
2-6-12|Rn-LA-WL 1960,34-1 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-11|12|792|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-12|Rn-LA-WL 1960,34-1 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-12|12|805|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-12|Rn-LA-WL 1960,34-1 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-13|12|841|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-12|Rn-LA-WL 1960,34-1 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-14|12|968|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-6-12|Rn-LA-WL 1960,34-1 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-15|12|968|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-6-12|Rn-LA-WL 1960,34-1 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-16|12|995|Neoplasia malignant|Lower respiratory system|n/a|
2-6-12|Rn-LA-WL 1960,34-1 12/78|2| 190|largactil|400|milligrams /l drink|Ingestion in food or water| 84 d in drinking water|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-1|12|399|Neoplasia systemic|Haematolymphatic system|n/a|
2-6-12|Rn-LA-WL 1960,34-1 12/78|2| 190|largactil|400|milligrams /l drink|Ingestion in food or water| 84 d in drinking water|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-2|12|496|Other deterministic changes|Lower respiratory system|n/a|
2-6-12|Rn-LA-WL 1960,34-1 12/78|2| 190|largactil|400|milligrams /l drink|Ingestion in food or water| 84 d in drinking water|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-3|12|527|Neoplasia malignant|Lower respiratory system|n/a|
2-6-12|Rn-LA-WL 1960,34-1 12/78|2| 190|largactil|400|milligrams /l drink|Ingestion in food or water| 84 d in drinking water|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-4|12|629|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-12|Rn-LA-WL 1960,34-1 12/78|2| 190|largactil|400|milligrams /l drink|Ingestion in food or water| 84 d in drinking water|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-5|12|685|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-6-12|Rn-LA-WL 1960,34-1 12/78|2| 190|largactil|400|milligrams /l drink|Ingestion in food or water| 84 d in drinking water|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-6|12|714|Other deterministic changes|Lower respiratory system|n/a|
2-6-12|Rn-LA-WL 1960,34-1 12/78|2| 190|largactil|400|milligrams /l drink|Ingestion in food or water| 84 d in drinking water|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-7|12|732|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|,MPATH: 215 - granulomatous inflammation|
2-6-12|Rn-LA-WL 1960,34-1 12/78|2| 190|largactil|400|milligrams /l drink|Ingestion in food or water| 84 d in drinking water|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-8|12|743|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland| metastatic,MPATH: 268 - adenocarcinoma|
2-6-12|Rn-LA-WL 1960,34-1 12/78|2| 190|largactil|400|milligrams /l drink|Ingestion in food or water| 84 d in drinking water|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-9|12|751|Neoplasia benign|Lower respiratory system|n/a|
2-6-12|Rn-LA-WL 1960,34-1 12/78|2| 190|largactil|400|milligrams /l drink|Ingestion in food or water| 84 d in drinking water|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-10|12|768|Other deterministic changes|Lower respiratory system|n/a|
2-6-12|Rn-LA-WL 1960,34-1 12/78|2| 190|largactil|400|milligrams /l drink|Ingestion in food or water| 84 d in drinking water|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-11|12|792|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-12|Rn-LA-WL 1960,34-1 12/78|2| 190|largactil|400|milligrams /l drink|Ingestion in food or water| 84 d in drinking water|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-12|12|805|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-12|Rn-LA-WL 1960,34-1 12/78|2| 190|largactil|400|milligrams /l drink|Ingestion in food or water| 84 d in drinking water|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-13|12|841|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-12|Rn-LA-WL 1960,34-1 12/78|2| 190|largactil|400|milligrams /l drink|Ingestion in food or water| 84 d in drinking water|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-14|12|968|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-6-12|Rn-LA-WL 1960,34-1 12/78|2| 190|largactil|400|milligrams /l drink|Ingestion in food or water| 84 d in drinking water|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-15|12|968|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-6-12|Rn-LA-WL 1960,34-1 12/78|2| 190|largactil|400|milligrams /l drink|Ingestion in food or water| 84 d in drinking water|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-12-16|12|995|Neoplasia malignant|Lower respiratory system|n/a|
2-6-13|Rn-PT-WL 1960,34-2 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 105200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-1|13|436|Other deterministic changes|Lower respiratory system|n/a|
2-6-13|Rn-PT-WL 1960,34-2 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 105200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-2|13|488|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|,MPATH: 215 - granulomatous inflammation|
2-6-13|Rn-PT-WL 1960,34-2 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 105200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-3|13|555|Neoplasia malignant|Lower respiratory system|n/a|
2-6-13|Rn-PT-WL 1960,34-2 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 105200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-4|13|586|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-13|Rn-PT-WL 1960,34-2 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 105200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-5|13|608|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract| metastatic,MPATH: 549 - carcinoma|
2-6-13|Rn-PT-WL 1960,34-2 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 105200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-6|13|659|Other deterministic changes|Lower respiratory system|n/a|
2-6-13|Rn-PT-WL 1960,34-2 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 105200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-7|13|680|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-6-13|Rn-PT-WL 1960,34-2 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 105200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-8|13|713|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-6-13|Rn-PT-WL 1960,34-2 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 105200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-9|13|765|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-13|Rn-PT-WL 1960,34-2 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 105200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-10|13|797|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-13|Rn-PT-WL 1960,34-2 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 105200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-11|13|887|Hyperplastic changes|Lower respiratory system|n/a|
2-6-13|Rn-PT-WL 1960,34-2 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 105200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-12|13|897|Hyperplastic changes|Lower respiratory system|n/a|
2-6-13|Rn-PT-WL 1960,34-2 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 105200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-13|13|898|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-6-13|Rn-PT-WL 1960,34-2 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 105200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-14|13|912|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-6-13|Rn-PT-WL 1960,34-2 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 105200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-15|13|937|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-13|Rn-PT-WL 1960,34-2 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 105200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-16|13|962|Neoplasia malignant|Upper respiratory system,MA: 0000442 - upper respiratory tract|,MPATH: 218 - neoplasm|
2-6-13|Rn-PT-WL 1960,34-2 12/78|2| 189|phenothiazine|40|milligrams per kg animal|Injection, intramuscular| 12x7 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-1|13|436|Other deterministic changes|Lower respiratory system|n/a|
2-6-13|Rn-PT-WL 1960,34-2 12/78|2| 189|phenothiazine|40|milligrams per kg animal|Injection, intramuscular| 12x7 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-2|13|488|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|,MPATH: 215 - granulomatous inflammation|
2-6-13|Rn-PT-WL 1960,34-2 12/78|2| 189|phenothiazine|40|milligrams per kg animal|Injection, intramuscular| 12x7 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-3|13|555|Neoplasia malignant|Lower respiratory system|n/a|
2-6-13|Rn-PT-WL 1960,34-2 12/78|2| 189|phenothiazine|40|milligrams per kg animal|Injection, intramuscular| 12x7 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-4|13|586|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-13|Rn-PT-WL 1960,34-2 12/78|2| 189|phenothiazine|40|milligrams per kg animal|Injection, intramuscular| 12x7 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-5|13|608|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract| metastatic,MPATH: 549 - carcinoma|
2-6-13|Rn-PT-WL 1960,34-2 12/78|2| 189|phenothiazine|40|milligrams per kg animal|Injection, intramuscular| 12x7 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-6|13|659|Other deterministic changes|Lower respiratory system|n/a|
2-6-13|Rn-PT-WL 1960,34-2 12/78|2| 189|phenothiazine|40|milligrams per kg animal|Injection, intramuscular| 12x7 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-7|13|680|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-6-13|Rn-PT-WL 1960,34-2 12/78|2| 189|phenothiazine|40|milligrams per kg animal|Injection, intramuscular| 12x7 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-8|13|713|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-6-13|Rn-PT-WL 1960,34-2 12/78|2| 189|phenothiazine|40|milligrams per kg animal|Injection, intramuscular| 12x7 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-9|13|765|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-13|Rn-PT-WL 1960,34-2 12/78|2| 189|phenothiazine|40|milligrams per kg animal|Injection, intramuscular| 12x7 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-10|13|797|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-13|Rn-PT-WL 1960,34-2 12/78|2| 189|phenothiazine|40|milligrams per kg animal|Injection, intramuscular| 12x7 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-11|13|887|Hyperplastic changes|Lower respiratory system|n/a|
2-6-13|Rn-PT-WL 1960,34-2 12/78|2| 189|phenothiazine|40|milligrams per kg animal|Injection, intramuscular| 12x7 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-12|13|897|Hyperplastic changes|Lower respiratory system|n/a|
2-6-13|Rn-PT-WL 1960,34-2 12/78|2| 189|phenothiazine|40|milligrams per kg animal|Injection, intramuscular| 12x7 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-13|13|898|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-6-13|Rn-PT-WL 1960,34-2 12/78|2| 189|phenothiazine|40|milligrams per kg animal|Injection, intramuscular| 12x7 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-14|13|912|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-6-13|Rn-PT-WL 1960,34-2 12/78|2| 189|phenothiazine|40|milligrams per kg animal|Injection, intramuscular| 12x7 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-15|13|937|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-13|Rn-PT-WL 1960,34-2 12/78|2| 189|phenothiazine|40|milligrams per kg animal|Injection, intramuscular| 12x7 d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-13-16|13|962|Neoplasia malignant|Upper respiratory system,MA: 0000442 - upper respiratory tract|,MPATH: 218 - neoplasm|
2-6-14|Rn-PR-WL 2240,38-2 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-1|14|500|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-14|Rn-PR-WL 2240,38-2 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-2|14|512|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-14|Rn-PR-WL 2240,38-2 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-3|14|582|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-6-14|Rn-PR-WL 2240,38-2 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-4|14|582|Neoplasia benign|Lower respiratory system|n/a|
2-6-14|Rn-PR-WL 2240,38-2 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-5|14|612|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-6-14|Rn-PR-WL 2240,38-2 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-6|14|667|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-14|Rn-PR-WL 2240,38-2 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-7|14|722|Neoplasia benign|Lower respiratory system|n/a|
2-6-14|Rn-PR-WL 2240,38-2 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-8|14|729|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-14|Rn-PR-WL 2240,38-2 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-9|14|749|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-14|Rn-PR-WL 2240,38-2 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-10|14|776|Hyperplastic changes|Lower respiratory system|n/a|
2-6-14|Rn-PR-WL 2240,38-2 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-11|14|803|Other deterministic changes|Lower respiratory system|n/a|
2-6-14|Rn-PR-WL 2240,38-2 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-12|14|812|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract| metastatic,MPATH: 549 - carcinoma|
2-6-14|Rn-PR-WL 2240,38-2 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-13|14|848|Hyperplastic changes|Lower respiratory system|n/a|
2-6-14|Rn-PR-WL 2240,38-2 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-14|14|848|Other deterministic changes|Lower respiratory system|n/a|
2-6-14|Rn-PR-WL 2240,38-2 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-15|14|866|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-6-14|Rn-PR-WL 2240,38-2 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-16|14|876|Neoplasia malignant|Lower respiratory system|n/a|
2-6-14|Rn-PR-WL 2240,38-2 4/79|2| 267|promethazine||unit code not relevant|Ingestion in food or water| Oral|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-1|14|500|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-14|Rn-PR-WL 2240,38-2 4/79|2| 267|promethazine||unit code not relevant|Ingestion in food or water| Oral|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-2|14|512|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-14|Rn-PR-WL 2240,38-2 4/79|2| 267|promethazine||unit code not relevant|Ingestion in food or water| Oral|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-3|14|582|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-6-14|Rn-PR-WL 2240,38-2 4/79|2| 267|promethazine||unit code not relevant|Ingestion in food or water| Oral|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-4|14|582|Neoplasia benign|Lower respiratory system|n/a|
2-6-14|Rn-PR-WL 2240,38-2 4/79|2| 267|promethazine||unit code not relevant|Ingestion in food or water| Oral|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-5|14|612|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-6-14|Rn-PR-WL 2240,38-2 4/79|2| 267|promethazine||unit code not relevant|Ingestion in food or water| Oral|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-6|14|667|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-14|Rn-PR-WL 2240,38-2 4/79|2| 267|promethazine||unit code not relevant|Ingestion in food or water| Oral|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-7|14|722|Neoplasia benign|Lower respiratory system|n/a|
2-6-14|Rn-PR-WL 2240,38-2 4/79|2| 267|promethazine||unit code not relevant|Ingestion in food or water| Oral|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-8|14|729|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-14|Rn-PR-WL 2240,38-2 4/79|2| 267|promethazine||unit code not relevant|Ingestion in food or water| Oral|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-9|14|749|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-14|Rn-PR-WL 2240,38-2 4/79|2| 267|promethazine||unit code not relevant|Ingestion in food or water| Oral|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-10|14|776|Hyperplastic changes|Lower respiratory system|n/a|
2-6-14|Rn-PR-WL 2240,38-2 4/79|2| 267|promethazine||unit code not relevant|Ingestion in food or water| Oral|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-11|14|803|Other deterministic changes|Lower respiratory system|n/a|
2-6-14|Rn-PR-WL 2240,38-2 4/79|2| 267|promethazine||unit code not relevant|Ingestion in food or water| Oral|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-12|14|812|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract| metastatic,MPATH: 549 - carcinoma|
2-6-14|Rn-PR-WL 2240,38-2 4/79|2| 267|promethazine||unit code not relevant|Ingestion in food or water| Oral|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-13|14|848|Hyperplastic changes|Lower respiratory system|n/a|
2-6-14|Rn-PR-WL 2240,38-2 4/79|2| 267|promethazine||unit code not relevant|Ingestion in food or water| Oral|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-14|14|848|Other deterministic changes|Lower respiratory system|n/a|
2-6-14|Rn-PR-WL 2240,38-2 4/79|2| 267|promethazine||unit code not relevant|Ingestion in food or water| Oral|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-15|14|866|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-6-14|Rn-PR-WL 2240,38-2 4/79|2| 267|promethazine||unit code not relevant|Ingestion in food or water| Oral|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-14-16|14|876|Neoplasia malignant|Lower respiratory system|n/a|
2-6-15|Rn-PB-WL 2100,19-8 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-1|15|528|Neoplasia benign|Lower respiratory system|n/a|
2-6-15|Rn-PB-WL 2100,19-8 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-2|15|549|Hyperplastic changes|Lower respiratory system|n/a|
2-6-15|Rn-PB-WL 2100,19-8 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-3|15|576|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| benign,MPATH: 408 - soft tissue fibrosarcoma|
2-6-15|Rn-PB-WL 2100,19-8 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-4|15|582|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-15|Rn-PB-WL 2100,19-8 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-5|15|590|Hyperplastic changes|Lower respiratory system|n/a|
2-6-15|Rn-PB-WL 2100,19-8 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-6|15|658|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-15|Rn-PB-WL 2100,19-8 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-7|15|685|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas| benign,MPATH: 268 - adenocarcinoma|
2-6-15|Rn-PB-WL 2100,19-8 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-8|15|703|Other deterministic changes|Lower respiratory system|n/a|
2-6-15|Rn-PB-WL 2100,19-8 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-9|15|764|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-6-15|Rn-PB-WL 2100,19-8 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-10|15|819|Neoplasia malignant|Lower respiratory system|n/a|
2-6-15|Rn-PB-WL 2100,19-8 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-11|15|822|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-6-15|Rn-PB-WL 2100,19-8 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-12|15|832|Neoplasia malignant|Lower respiratory system|n/a|
2-6-15|Rn-PB-WL 2100,19-8 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-13|15|851|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-6-15|Rn-PB-WL 2100,19-8 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-14|15|891|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-6-15|Rn-PB-WL 2100,19-8 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-15|15|919|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-6-15|Rn-PB-WL 2100,19-8 1/76|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-16|15|919|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-6-15|Rn-PB-WL 2100,19-8 1/76|2| 442|phenobarbital|80|milligrams per kg animal|Injection, intraperitoneal| IP inject 12x7d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-1|15|528|Neoplasia benign|Lower respiratory system|n/a|
2-6-15|Rn-PB-WL 2100,19-8 1/76|2| 442|phenobarbital|80|milligrams per kg animal|Injection, intraperitoneal| IP inject 12x7d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-2|15|549|Hyperplastic changes|Lower respiratory system|n/a|
2-6-15|Rn-PB-WL 2100,19-8 1/76|2| 442|phenobarbital|80|milligrams per kg animal|Injection, intraperitoneal| IP inject 12x7d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-3|15|576|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| benign,MPATH: 408 - soft tissue fibrosarcoma|
2-6-15|Rn-PB-WL 2100,19-8 1/76|2| 442|phenobarbital|80|milligrams per kg animal|Injection, intraperitoneal| IP inject 12x7d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-4|15|582|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-15|Rn-PB-WL 2100,19-8 1/76|2| 442|phenobarbital|80|milligrams per kg animal|Injection, intraperitoneal| IP inject 12x7d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-5|15|590|Hyperplastic changes|Lower respiratory system|n/a|
2-6-15|Rn-PB-WL 2100,19-8 1/76|2| 442|phenobarbital|80|milligrams per kg animal|Injection, intraperitoneal| IP inject 12x7d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-6|15|658|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-15|Rn-PB-WL 2100,19-8 1/76|2| 442|phenobarbital|80|milligrams per kg animal|Injection, intraperitoneal| IP inject 12x7d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-7|15|685|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas| benign,MPATH: 268 - adenocarcinoma|
2-6-15|Rn-PB-WL 2100,19-8 1/76|2| 442|phenobarbital|80|milligrams per kg animal|Injection, intraperitoneal| IP inject 12x7d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-8|15|703|Other deterministic changes|Lower respiratory system|n/a|
2-6-15|Rn-PB-WL 2100,19-8 1/76|2| 442|phenobarbital|80|milligrams per kg animal|Injection, intraperitoneal| IP inject 12x7d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-9|15|764|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-6-15|Rn-PB-WL 2100,19-8 1/76|2| 442|phenobarbital|80|milligrams per kg animal|Injection, intraperitoneal| IP inject 12x7d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-10|15|819|Neoplasia malignant|Lower respiratory system|n/a|
2-6-15|Rn-PB-WL 2100,19-8 1/76|2| 442|phenobarbital|80|milligrams per kg animal|Injection, intraperitoneal| IP inject 12x7d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-11|15|822|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-6-15|Rn-PB-WL 2100,19-8 1/76|2| 442|phenobarbital|80|milligrams per kg animal|Injection, intraperitoneal| IP inject 12x7d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-12|15|832|Neoplasia malignant|Lower respiratory system|n/a|
2-6-15|Rn-PB-WL 2100,19-8 1/76|2| 442|phenobarbital|80|milligrams per kg animal|Injection, intraperitoneal| IP inject 12x7d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-13|15|851|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-6-15|Rn-PB-WL 2100,19-8 1/76|2| 442|phenobarbital|80|milligrams per kg animal|Injection, intraperitoneal| IP inject 12x7d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-14|15|891|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-6-15|Rn-PB-WL 2100,19-8 1/76|2| 442|phenobarbital|80|milligrams per kg animal|Injection, intraperitoneal| IP inject 12x7d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-15|15|919|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-6-15|Rn-PB-WL 2100,19-8 1/76|2| 442|phenobarbital|80|milligrams per kg animal|Injection, intraperitoneal| IP inject 12x7d|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-15-16|15|919|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-6-16|Rn-PB-WL 2240,28-4 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-16-1|16|571|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-16|Rn-PB-WL 2240,28-4 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-16-2|16|619|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-6-16|Rn-PB-WL 2240,28-4 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-16-3|16|669|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-16|Rn-PB-WL 2240,28-4 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-16-4|16|710|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 218 - neoplasm|
2-6-16|Rn-PB-WL 2240,28-4 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-16-5|16|746|Neoplasia malignant|Lower respiratory system|n/a|
2-6-16|Rn-PB-WL 2240,28-4 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-16-6|16|746|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-6-16|Rn-PB-WL 2240,28-4 4/79|2| 267|phenobarbital|80|milligrams per kg animal|Injection, intraperitoneal| IP inject 12x7d (2)+ cont. oral|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-16-1|16|571|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-16|Rn-PB-WL 2240,28-4 4/79|2| 267|phenobarbital|80|milligrams per kg animal|Injection, intraperitoneal| IP inject 12x7d (2)+ cont. oral|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-16-2|16|619|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-6-16|Rn-PB-WL 2240,28-4 4/79|2| 267|phenobarbital|80|milligrams per kg animal|Injection, intraperitoneal| IP inject 12x7d (2)+ cont. oral|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-16-3|16|669|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-16|Rn-PB-WL 2240,28-4 4/79|2| 267|phenobarbital|80|milligrams per kg animal|Injection, intraperitoneal| IP inject 12x7d (2)+ cont. oral|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-16-4|16|710|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 218 - neoplasm|
2-6-16|Rn-PB-WL 2240,28-4 4/79|2| 267|phenobarbital|80|milligrams per kg animal|Injection, intraperitoneal| IP inject 12x7d (2)+ cont. oral|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-16-5|16|746|Neoplasia malignant|Lower respiratory system|n/a|
2-6-16|Rn-PB-WL 2240,28-4 4/79|2| 267|phenobarbital|80|milligrams per kg animal|Injection, intraperitoneal| IP inject 12x7d (2)+ cont. oral|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-16-6|16|746|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-6-17|Rn-IN-WL 1000,21 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-17-1|17|502|Other deterministic changes|Lower respiratory system|n/a|
2-6-17|Rn-IN-WL 1000,21 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-17-2|17|535|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-17|Rn-IN-WL 1000,21 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-17-3|17|544|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-17|Rn-IN-WL 1000,21 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-17-4|17|550|Neoplasia malignant|Lower respiratory system|n/a|
2-6-17|Rn-IN-WL 1000,21 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-17-5|17|570|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-17|Rn-IN-WL 1000,21 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-17-6|17|583|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-17|Rn-IN-WL 1000,21 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-17-7|17|592|Neoplasia malignant|Lower respiratory system|n/a|
2-6-17|Rn-IN-WL 1000,21 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-17-8|17|622|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-17|Rn-IN-WL 1000,21 4/77|2| 246|isonicotinic acid hydrazide|35|milligrams per kg animal|Injection, intraperitoneal| 12x7 d IP inject.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-17-1|17|502|Other deterministic changes|Lower respiratory system|n/a|
2-6-17|Rn-IN-WL 1000,21 4/77|2| 246|isonicotinic acid hydrazide|35|milligrams per kg animal|Injection, intraperitoneal| 12x7 d IP inject.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-17-2|17|535|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-17|Rn-IN-WL 1000,21 4/77|2| 246|isonicotinic acid hydrazide|35|milligrams per kg animal|Injection, intraperitoneal| 12x7 d IP inject.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-17-3|17|544|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-17|Rn-IN-WL 1000,21 4/77|2| 246|isonicotinic acid hydrazide|35|milligrams per kg animal|Injection, intraperitoneal| 12x7 d IP inject.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-17-4|17|550|Neoplasia malignant|Lower respiratory system|n/a|
2-6-17|Rn-IN-WL 1000,21 4/77|2| 246|isonicotinic acid hydrazide|35|milligrams per kg animal|Injection, intraperitoneal| 12x7 d IP inject.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-17-5|17|570|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-17|Rn-IN-WL 1000,21 4/77|2| 246|isonicotinic acid hydrazide|35|milligrams per kg animal|Injection, intraperitoneal| 12x7 d IP inject.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-17-6|17|583|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-17|Rn-IN-WL 1000,21 4/77|2| 246|isonicotinic acid hydrazide|35|milligrams per kg animal|Injection, intraperitoneal| 12x7 d IP inject.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-17-7|17|592|Neoplasia malignant|Lower respiratory system|n/a|
2-6-17|Rn-IN-WL 1000,21 4/77|2| 246|isonicotinic acid hydrazide|35|milligrams per kg animal|Injection, intraperitoneal| 12x7 d IP inject.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-17-8|17|622|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-18|Rn-IN-WL 1960,33-3 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-1|18|432|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-18|Rn-IN-WL 1960,33-3 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-2|18|434|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-18|Rn-IN-WL 1960,33-3 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-3|18|567|Other deterministic changes|Lower respiratory system|n/a|
2-6-18|Rn-IN-WL 1960,33-3 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-4|18|636|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-18|Rn-IN-WL 1960,33-3 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-5|18|694|Neoplasia malignant|Bloodvessels among cardiovascular system| metastatic|
2-6-18|Rn-IN-WL 1960,33-3 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-6|18|694|Neoplasia malignant|Upper respiratory system,MA: 0000442 - upper respiratory tract|,MPATH: 218 - neoplasm|
2-6-18|Rn-IN-WL 1960,33-3 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-7|18|694|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-6-18|Rn-IN-WL 1960,33-3 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-8|18|761|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-6-18|Rn-IN-WL 1960,33-3 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-9|18|762|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-6-18|Rn-IN-WL 1960,33-3 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-10|18|762|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-6-18|Rn-IN-WL 1960,33-3 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-11|18|782|Neoplasia malignant|Lower respiratory system|n/a|
2-6-18|Rn-IN-WL 1960,33-3 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-12|18|786|Hyperplastic changes|Lower respiratory system|n/a|
2-6-18|Rn-IN-WL 1960,33-3 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-13|18|786|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-6-18|Rn-IN-WL 1960,33-3 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-14|18|786|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-18|Rn-IN-WL 1960,33-3 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-15|18|803|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-18|Rn-IN-WL 1960,33-3 12/78|1| 77|Rn-222 gas|1960|working level months|Inhalation| inhaled over 2 m at 1050 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-16|18|874|Neoplasia malignant|Lower respiratory system|n/a|
2-6-18|Rn-IN-WL 1960,33-3 12/78|2| 195|isonicotinic acid hydrazide|35|milligrams per kg animal|Injection, intraperitoneal| 12x7 d (x2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-1|18|432|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-18|Rn-IN-WL 1960,33-3 12/78|2| 195|isonicotinic acid hydrazide|35|milligrams per kg animal|Injection, intraperitoneal| 12x7 d (x2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-2|18|434|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-18|Rn-IN-WL 1960,33-3 12/78|2| 195|isonicotinic acid hydrazide|35|milligrams per kg animal|Injection, intraperitoneal| 12x7 d (x2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-3|18|567|Other deterministic changes|Lower respiratory system|n/a|
2-6-18|Rn-IN-WL 1960,33-3 12/78|2| 195|isonicotinic acid hydrazide|35|milligrams per kg animal|Injection, intraperitoneal| 12x7 d (x2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-4|18|636|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-18|Rn-IN-WL 1960,33-3 12/78|2| 195|isonicotinic acid hydrazide|35|milligrams per kg animal|Injection, intraperitoneal| 12x7 d (x2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-5|18|694|Neoplasia malignant|Bloodvessels among cardiovascular system| metastatic|
2-6-18|Rn-IN-WL 1960,33-3 12/78|2| 195|isonicotinic acid hydrazide|35|milligrams per kg animal|Injection, intraperitoneal| 12x7 d (x2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-6|18|694|Neoplasia malignant|Upper respiratory system,MA: 0000442 - upper respiratory tract|,MPATH: 218 - neoplasm|
2-6-18|Rn-IN-WL 1960,33-3 12/78|2| 195|isonicotinic acid hydrazide|35|milligrams per kg animal|Injection, intraperitoneal| 12x7 d (x2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-7|18|694|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-6-18|Rn-IN-WL 1960,33-3 12/78|2| 195|isonicotinic acid hydrazide|35|milligrams per kg animal|Injection, intraperitoneal| 12x7 d (x2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-8|18|761|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-6-18|Rn-IN-WL 1960,33-3 12/78|2| 195|isonicotinic acid hydrazide|35|milligrams per kg animal|Injection, intraperitoneal| 12x7 d (x2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-9|18|762|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-6-18|Rn-IN-WL 1960,33-3 12/78|2| 195|isonicotinic acid hydrazide|35|milligrams per kg animal|Injection, intraperitoneal| 12x7 d (x2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-10|18|762|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-6-18|Rn-IN-WL 1960,33-3 12/78|2| 195|isonicotinic acid hydrazide|35|milligrams per kg animal|Injection, intraperitoneal| 12x7 d (x2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-11|18|782|Neoplasia malignant|Lower respiratory system|n/a|
2-6-18|Rn-IN-WL 1960,33-3 12/78|2| 195|isonicotinic acid hydrazide|35|milligrams per kg animal|Injection, intraperitoneal| 12x7 d (x2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-12|18|786|Hyperplastic changes|Lower respiratory system|n/a|
2-6-18|Rn-IN-WL 1960,33-3 12/78|2| 195|isonicotinic acid hydrazide|35|milligrams per kg animal|Injection, intraperitoneal| 12x7 d (x2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-13|18|786|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-6-18|Rn-IN-WL 1960,33-3 12/78|2| 195|isonicotinic acid hydrazide|35|milligrams per kg animal|Injection, intraperitoneal| 12x7 d (x2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-14|18|786|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-18|Rn-IN-WL 1960,33-3 12/78|2| 195|isonicotinic acid hydrazide|35|milligrams per kg animal|Injection, intraperitoneal| 12x7 d (x2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-15|18|803|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-18|Rn-IN-WL 1960,33-3 12/78|2| 195|isonicotinic acid hydrazide|35|milligrams per kg animal|Injection, intraperitoneal| 12x7 d (x2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-18-16|18|874|Neoplasia malignant|Lower respiratory system|n/a|
2-6-19|Rn-RI-WL 1000,28-1 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-19-1|19|495|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-19|Rn-RI-WL 1000,28-1 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-19-2|19|495|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-19|Rn-RI-WL 1000,28-1 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-19-3|19|509|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-6-19|Rn-RI-WL 1000,28-1 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-19-4|19|514|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-19|Rn-RI-WL 1000,28-1 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-19-5|19|553|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-19|Rn-RI-WL 1000,28-1 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-19-6|19|560|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
2-6-19|Rn-RI-WL 1000,28-1 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-19-7|19|570|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-19|Rn-RI-WL 1000,28-1 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-19-8|19|590|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-19|Rn-RI-WL 1000,28-1 4/77|2| 78|rifampicine|50|milligrams per kg animal|Injection, intraperitoneal| 2*/w IP inject.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-19-1|19|495|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-19|Rn-RI-WL 1000,28-1 4/77|2| 78|rifampicine|50|milligrams per kg animal|Injection, intraperitoneal| 2*/w IP inject.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-19-2|19|495|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-19|Rn-RI-WL 1000,28-1 4/77|2| 78|rifampicine|50|milligrams per kg animal|Injection, intraperitoneal| 2*/w IP inject.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-19-3|19|509|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-6-19|Rn-RI-WL 1000,28-1 4/77|2| 78|rifampicine|50|milligrams per kg animal|Injection, intraperitoneal| 2*/w IP inject.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-19-4|19|514|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-19|Rn-RI-WL 1000,28-1 4/77|2| 78|rifampicine|50|milligrams per kg animal|Injection, intraperitoneal| 2*/w IP inject.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-19-5|19|553|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-19|Rn-RI-WL 1000,28-1 4/77|2| 78|rifampicine|50|milligrams per kg animal|Injection, intraperitoneal| 2*/w IP inject.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-19-6|19|560|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
2-6-19|Rn-RI-WL 1000,28-1 4/77|2| 78|rifampicine|50|milligrams per kg animal|Injection, intraperitoneal| 2*/w IP inject.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-19-7|19|570|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-19|Rn-RI-WL 1000,28-1 4/77|2| 78|rifampicine|50|milligrams per kg animal|Injection, intraperitoneal| 2*/w IP inject.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-19-8|19|590|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-20|Rn-RI-WL 2240,38-1 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-1|20|281|Other deterministic changes|Lower respiratory system|n/a|
2-6-20|Rn-RI-WL 2240,38-1 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-2|20|293|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-20|Rn-RI-WL 2240,38-1 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-3|20|297|Other deterministic changes|Lower respiratory system|n/a|
2-6-20|Rn-RI-WL 2240,38-1 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-4|20|311|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-6-20|Rn-RI-WL 2240,38-1 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-5|20|335|Other deterministic changes|Lower respiratory system|n/a|
2-6-20|Rn-RI-WL 2240,38-1 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-6|20|346|Other deterministic changes|Lower respiratory system|n/a|
2-6-20|Rn-RI-WL 2240,38-1 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-7|20|375|Other deterministic changes|Lower respiratory system|n/a|
2-6-20|Rn-RI-WL 2240,38-1 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-8|20|380|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-6-20|Rn-RI-WL 2240,38-1 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-9|20|392|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-20|Rn-RI-WL 2240,38-1 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-10|20|560|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-6-20|Rn-RI-WL 2240,38-1 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-11|20|638|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-6-20|Rn-RI-WL 2240,38-1 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-12|20|688|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 426 - leiomyosarcoma|
2-6-20|Rn-RI-WL 2240,38-1 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-13|20|716|Neoplasia benign|Lower respiratory system|n/a|
2-6-20|Rn-RI-WL 2240,38-1 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-14|20|722|Neoplasia malignant|Lower respiratory system|n/a|
2-6-20|Rn-RI-WL 2240,38-1 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-15|20|793|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-6-20|Rn-RI-WL 2240,38-1 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-16|20|857|Neoplasia malignant|Lower respiratory system|n/a|
2-6-20|Rn-RI-WL 2240,38-1 4/79|2| 267|rifampicine|50|milligrams per kg animal|Inhalation| 12x7d(2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-1|20|281|Other deterministic changes|Lower respiratory system|n/a|
2-6-20|Rn-RI-WL 2240,38-1 4/79|2| 267|rifampicine|50|milligrams per kg animal|Inhalation| 12x7d(2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-2|20|293|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-20|Rn-RI-WL 2240,38-1 4/79|2| 267|rifampicine|50|milligrams per kg animal|Inhalation| 12x7d(2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-3|20|297|Other deterministic changes|Lower respiratory system|n/a|
2-6-20|Rn-RI-WL 2240,38-1 4/79|2| 267|rifampicine|50|milligrams per kg animal|Inhalation| 12x7d(2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-4|20|311|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-6-20|Rn-RI-WL 2240,38-1 4/79|2| 267|rifampicine|50|milligrams per kg animal|Inhalation| 12x7d(2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-5|20|335|Other deterministic changes|Lower respiratory system|n/a|
2-6-20|Rn-RI-WL 2240,38-1 4/79|2| 267|rifampicine|50|milligrams per kg animal|Inhalation| 12x7d(2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-6|20|346|Other deterministic changes|Lower respiratory system|n/a|
2-6-20|Rn-RI-WL 2240,38-1 4/79|2| 267|rifampicine|50|milligrams per kg animal|Inhalation| 12x7d(2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-7|20|375|Other deterministic changes|Lower respiratory system|n/a|
2-6-20|Rn-RI-WL 2240,38-1 4/79|2| 267|rifampicine|50|milligrams per kg animal|Inhalation| 12x7d(2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-8|20|380|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-6-20|Rn-RI-WL 2240,38-1 4/79|2| 267|rifampicine|50|milligrams per kg animal|Inhalation| 12x7d(2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-9|20|392|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-6-20|Rn-RI-WL 2240,38-1 4/79|2| 267|rifampicine|50|milligrams per kg animal|Inhalation| 12x7d(2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-10|20|560|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-6-20|Rn-RI-WL 2240,38-1 4/79|2| 267|rifampicine|50|milligrams per kg animal|Inhalation| 12x7d(2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-11|20|638|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-6-20|Rn-RI-WL 2240,38-1 4/79|2| 267|rifampicine|50|milligrams per kg animal|Inhalation| 12x7d(2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-12|20|688|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 426 - leiomyosarcoma|
2-6-20|Rn-RI-WL 2240,38-1 4/79|2| 267|rifampicine|50|milligrams per kg animal|Inhalation| 12x7d(2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-13|20|716|Neoplasia benign|Lower respiratory system|n/a|
2-6-20|Rn-RI-WL 2240,38-1 4/79|2| 267|rifampicine|50|milligrams per kg animal|Inhalation| 12x7d(2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-14|20|722|Neoplasia malignant|Lower respiratory system|n/a|
2-6-20|Rn-RI-WL 2240,38-1 4/79|2| 267|rifampicine|50|milligrams per kg animal|Inhalation| 12x7d(2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-15|20|793|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-6-20|Rn-RI-WL 2240,38-1 4/79|2| 267|rifampicine|50|milligrams per kg animal|Inhalation| 12x7d(2) IP inject.|16 (16 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-20-16|20|857|Neoplasia malignant|Lower respiratory system|n/a|
2-6-21|Rn-AC-WL 1000,28-4 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-21-1|21|444|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 426 - leiomyosarcoma|
2-6-21|Rn-AC-WL 1000,28-4 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-21-2|21|461|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-21|Rn-AC-WL 1000,28-4 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-21-3|21|461|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-6-21|Rn-AC-WL 1000,28-4 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-21-4|21|502|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-21|Rn-AC-WL 1000,28-4 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-21-5|21|531|Other deterministic changes|Whole body|n/a|
2-6-21|Rn-AC-WL 1000,28-4 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-21-6|21|547|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-21|Rn-AC-WL 1000,28-4 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-21-7|21|554|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-21|Rn-AC-WL 1000,28-4 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-21-8|21|577|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-21|Rn-AC-WL 1000,28-4 4/77|2| 247|acetylaminfluorene|0.6|milligrams per kg animal|not applicable or not supplied| for 12 w|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-21-1|21|444|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 426 - leiomyosarcoma|
2-6-21|Rn-AC-WL 1000,28-4 4/77|2| 247|acetylaminfluorene|0.6|milligrams per kg animal|not applicable or not supplied| for 12 w|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-21-2|21|461|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-21|Rn-AC-WL 1000,28-4 4/77|2| 247|acetylaminfluorene|0.6|milligrams per kg animal|not applicable or not supplied| for 12 w|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-21-3|21|461|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-6-21|Rn-AC-WL 1000,28-4 4/77|2| 247|acetylaminfluorene|0.6|milligrams per kg animal|not applicable or not supplied| for 12 w|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-21-4|21|502|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-21|Rn-AC-WL 1000,28-4 4/77|2| 247|acetylaminfluorene|0.6|milligrams per kg animal|not applicable or not supplied| for 12 w|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-21-5|21|531|Other deterministic changes|Whole body|n/a|
2-6-21|Rn-AC-WL 1000,28-4 4/77|2| 247|acetylaminfluorene|0.6|milligrams per kg animal|not applicable or not supplied| for 12 w|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-21-6|21|547|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-21|Rn-AC-WL 1000,28-4 4/77|2| 247|acetylaminfluorene|0.6|milligrams per kg animal|not applicable or not supplied| for 12 w|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-21-7|21|554|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-21|Rn-AC-WL 1000,28-4 4/77|2| 247|acetylaminfluorene|0.6|milligrams per kg animal|not applicable or not supplied| for 12 w|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-21-8|21|577|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-22|Rn-PM-WL 1000,28-5 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-22-1|22|401|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-22|Rn-PM-WL 1000,28-5 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-22-2|22|474|Other deterministic changes|Lower respiratory system|n/a|
2-6-22|Rn-PM-WL 1000,28-5 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-22-3|22|504|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-22|Rn-PM-WL 1000,28-5 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-22-4|22|504|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-22|Rn-PM-WL 1000,28-5 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-22-5|22|536|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-22|Rn-PM-WL 1000,28-5 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-22-6|22|540|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-22|Rn-PM-WL 1000,28-5 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-22-7|22|557|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-22|Rn-PM-WL 1000,28-5 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-22-8|22|557|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-22|Rn-PM-WL 1000,28-5 4/77|2| 248|pentamethyl-quercetine||unit code not relevant|not applicable or not supplied| quantity unknown|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-22-1|22|401|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-22|Rn-PM-WL 1000,28-5 4/77|2| 248|pentamethyl-quercetine||unit code not relevant|not applicable or not supplied| quantity unknown|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-22-2|22|474|Other deterministic changes|Lower respiratory system|n/a|
2-6-22|Rn-PM-WL 1000,28-5 4/77|2| 248|pentamethyl-quercetine||unit code not relevant|not applicable or not supplied| quantity unknown|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-22-3|22|504|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-22|Rn-PM-WL 1000,28-5 4/77|2| 248|pentamethyl-quercetine||unit code not relevant|not applicable or not supplied| quantity unknown|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-22-4|22|504|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-22|Rn-PM-WL 1000,28-5 4/77|2| 248|pentamethyl-quercetine||unit code not relevant|not applicable or not supplied| quantity unknown|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-22-5|22|536|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-22|Rn-PM-WL 1000,28-5 4/77|2| 248|pentamethyl-quercetine||unit code not relevant|not applicable or not supplied| quantity unknown|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-22-6|22|540|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-22|Rn-PM-WL 1000,28-5 4/77|2| 248|pentamethyl-quercetine||unit code not relevant|not applicable or not supplied| quantity unknown|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-22-7|22|557|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-22|Rn-PM-WL 1000,28-5 4/77|2| 248|pentamethyl-quercetine||unit code not relevant|not applicable or not supplied| quantity unknown|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-22-8|22|557|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-23|Rn-BC-WL 2800,14 2/74|1| 77|Rn-222 gas|2800|working level months|Inhalation| inhaled over 3 m at 1050 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-1|23|399|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-23|Rn-BC-WL 2800,14 2/74|1| 77|Rn-222 gas|2800|working level months|Inhalation| inhaled over 3 m at 1050 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-2|23|407|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-6-23|Rn-BC-WL 2800,14 2/74|1| 77|Rn-222 gas|2800|working level months|Inhalation| inhaled over 3 m at 1050 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-3|23|535|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-23|Rn-BC-WL 2800,14 2/74|1| 77|Rn-222 gas|2800|working level months|Inhalation| inhaled over 3 m at 1050 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-4|23|557|Other deterministic changes|Whole body|n/a|
2-6-23|Rn-BC-WL 2800,14 2/74|1| 77|Rn-222 gas|2800|working level months|Inhalation| inhaled over 3 m at 1050 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-5|23|590|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-23|Rn-BC-WL 2800,14 2/74|1| 77|Rn-222 gas|2800|working level months|Inhalation| inhaled over 3 m at 1050 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-6|23|599|Other deterministic changes|Whole body|n/a|
2-6-23|Rn-BC-WL 2800,14 2/74|1| 77|Rn-222 gas|2800|working level months|Inhalation| inhaled over 3 m at 1050 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-7|23|638|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-6-23|Rn-BC-WL 2800,14 2/74|1| 77|Rn-222 gas|2800|working level months|Inhalation| inhaled over 3 m at 1050 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-8|23|638|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-6-23|Rn-BC-WL 2800,14 2/74|1| 77|Rn-222 gas|2800|working level months|Inhalation| inhaled over 3 m at 1050 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-9|23|651|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-6-23|Rn-BC-WL 2800,14 2/74|1| 77|Rn-222 gas|2800|working level months|Inhalation| inhaled over 3 m at 1050 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-10|23|662|Hyperplastic changes|Lower respiratory system|n/a|
2-6-23|Rn-BC-WL 2800,14 2/74|1| 77|Rn-222 gas|2800|working level months|Inhalation| inhaled over 3 m at 1050 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-11|23|683|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-23|Rn-BC-WL 2800,14 2/74|1| 77|Rn-222 gas|2800|working level months|Inhalation| inhaled over 3 m at 1050 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-12|23|690|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-23|Rn-BC-WL 2800,14 2/74|1| 77|Rn-222 gas|2800|working level months|Inhalation| inhaled over 3 m at 1050 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-13|23|692|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-23|Rn-BC-WL 2800,14 2/74|1| 77|Rn-222 gas|2800|working level months|Inhalation| inhaled over 3 m at 1050 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-14|23|708|Neoplasia malignant|Lower respiratory system|n/a|
2-6-23|Rn-BC-WL 2800,14 2/74|1| 77|Rn-222 gas|2800|working level months|Inhalation| inhaled over 3 m at 1050 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-15|23|739|Neoplasia malignant|Lower respiratory system|n/a|
2-6-23|Rn-BC-WL 2800,14 2/74|1| 77|Rn-222 gas|2800|working level months|Inhalation| inhaled over 3 m at 1050 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-16|23|750|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-23|Rn-BC-WL 2800,14 2/74|1| 77|Rn-222 gas|2800|working level months|Inhalation| inhaled over 3 m at 1050 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-17|23|755|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-23|Rn-BC-WL 2800,14 2/74|1| 77|Rn-222 gas|2800|working level months|Inhalation| inhaled over 3 m at 1050 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-18|23|809|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-23|Rn-BC-WL 2800,14 2/74|1| 77|Rn-222 gas|2800|working level months|Inhalation| inhaled over 3 m at 1050 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-19|23|818|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-23|Rn-BC-WL 2800,14 2/74|1| 77|Rn-222 gas|2800|working level months|Inhalation| inhaled over 3 m at 1050 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-20|23|818|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-6-23|Rn-BC-WL 2800,14 2/74|2| 78|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-1|23|399|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-23|Rn-BC-WL 2800,14 2/74|2| 78|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-2|23|407|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-6-23|Rn-BC-WL 2800,14 2/74|2| 78|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-3|23|535|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-23|Rn-BC-WL 2800,14 2/74|2| 78|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-4|23|557|Other deterministic changes|Whole body|n/a|
2-6-23|Rn-BC-WL 2800,14 2/74|2| 78|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-5|23|590|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-23|Rn-BC-WL 2800,14 2/74|2| 78|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-6|23|599|Other deterministic changes|Whole body|n/a|
2-6-23|Rn-BC-WL 2800,14 2/74|2| 78|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-7|23|638|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-6-23|Rn-BC-WL 2800,14 2/74|2| 78|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-8|23|638|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-6-23|Rn-BC-WL 2800,14 2/74|2| 78|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-9|23|651|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-6-23|Rn-BC-WL 2800,14 2/74|2| 78|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-10|23|662|Hyperplastic changes|Lower respiratory system|n/a|
2-6-23|Rn-BC-WL 2800,14 2/74|2| 78|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-11|23|683|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-23|Rn-BC-WL 2800,14 2/74|2| 78|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-12|23|690|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-23|Rn-BC-WL 2800,14 2/74|2| 78|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-13|23|692|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-23|Rn-BC-WL 2800,14 2/74|2| 78|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-14|23|708|Neoplasia malignant|Lower respiratory system|n/a|
2-6-23|Rn-BC-WL 2800,14 2/74|2| 78|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-15|23|739|Neoplasia malignant|Lower respiratory system|n/a|
2-6-23|Rn-BC-WL 2800,14 2/74|2| 78|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-16|23|750|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-23|Rn-BC-WL 2800,14 2/74|2| 78|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-17|23|755|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-23|Rn-BC-WL 2800,14 2/74|2| 78|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-18|23|809|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-23|Rn-BC-WL 2800,14 2/74|2| 78|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-19|23|818|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-6-23|Rn-BC-WL 2800,14 2/74|2| 78|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-23-20|23|818|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-6-24|Rn-BC-WL 2100,18-4 1/76|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-1|24|526|Other deterministic changes|Whole body|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-2|24|551|Other deterministic changes|Lower respiratory system|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-3|24|649|Other deterministic changes|Lower respiratory system|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-4|24|674|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
2-6-24|Rn-BC-WL 2100,18-4 1/76|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-5|24|676|Other deterministic changes|Lower respiratory system|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-6|24|715|Other deterministic changes|Whole body|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-7|24|748|Other deterministic changes|Whole body|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-8|24|748|Other deterministic changes|Whole body|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-9|24|758|Other deterministic changes|Whole body|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-10|24|766|Other deterministic changes|Whole body|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-11|24|771|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-24|Rn-BC-WL 2100,18-4 1/76|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-12|24|780|Other deterministic changes|Whole body|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-13|24|785|Other deterministic changes|Whole body|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-14|24|799|Hyperplastic changes|Lower respiratory system|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-15|24|799|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-24|Rn-BC-WL 2100,18-4 1/76|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-16|24|802|Other deterministic changes|Whole body|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-17|24|814|Hyperplastic changes|Lower respiratory system|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-18|24|823|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-24|Rn-BC-WL 2100,18-4 1/76|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-19|24|846|Hyperplastic changes|Lower respiratory system|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-20|24|847|Neoplasia malignant|Lower respiratory system|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-21|24|850|Hyperplastic changes|Lower respiratory system|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-22|24|854|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-24|Rn-BC-WL 2100,18-4 1/76|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-23|24|864|Other deterministic changes|Lower respiratory system|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-24|24|866|Hyperplastic changes|Lower respiratory system|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-25|24|896|Hyperplastic changes|Lower respiratory system|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-26|24|901|Other deterministic changes|Lower respiratory system|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-27|24|903|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-24|Rn-BC-WL 2100,18-4 1/76|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-28|24|910|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-24|Rn-BC-WL 2100,18-4 1/76|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-29|24|910|Neoplasia malignant|Lower respiratory system|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|1| 153|Rn-222 gas|2100|working level months|Inhalation| inhaled over 2 m at 1050 WL|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-30|24|931|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-24|Rn-BC-WL 2100,18-4 1/76|2| 603|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-1|24|526|Other deterministic changes|Whole body|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|2| 603|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-2|24|551|Other deterministic changes|Lower respiratory system|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|2| 603|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-3|24|649|Other deterministic changes|Lower respiratory system|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|2| 603|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-4|24|674|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
2-6-24|Rn-BC-WL 2100,18-4 1/76|2| 603|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-5|24|676|Other deterministic changes|Lower respiratory system|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|2| 603|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-6|24|715|Other deterministic changes|Whole body|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|2| 603|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-7|24|748|Other deterministic changes|Whole body|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|2| 603|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-8|24|748|Other deterministic changes|Whole body|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|2| 603|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-9|24|758|Other deterministic changes|Whole body|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|2| 603|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-10|24|766|Other deterministic changes|Whole body|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|2| 603|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-11|24|771|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-24|Rn-BC-WL 2100,18-4 1/76|2| 603|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-12|24|780|Other deterministic changes|Whole body|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|2| 603|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-13|24|785|Other deterministic changes|Whole body|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|2| 603|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-14|24|799|Hyperplastic changes|Lower respiratory system|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|2| 603|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-15|24|799|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-24|Rn-BC-WL 2100,18-4 1/76|2| 603|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-16|24|802|Other deterministic changes|Whole body|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|2| 603|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-17|24|814|Hyperplastic changes|Lower respiratory system|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|2| 603|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-18|24|823|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-24|Rn-BC-WL 2100,18-4 1/76|2| 603|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-19|24|846|Hyperplastic changes|Lower respiratory system|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|2| 603|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-20|24|847|Neoplasia malignant|Lower respiratory system|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|2| 603|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-21|24|850|Hyperplastic changes|Lower respiratory system|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|2| 603|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-22|24|854|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-24|Rn-BC-WL 2100,18-4 1/76|2| 603|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-23|24|864|Other deterministic changes|Lower respiratory system|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|2| 603|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-24|24|866|Hyperplastic changes|Lower respiratory system|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|2| 603|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-25|24|896|Hyperplastic changes|Lower respiratory system|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|2| 603|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-26|24|901|Other deterministic changes|Lower respiratory system|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|2| 603|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-27|24|903|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-24|Rn-BC-WL 2100,18-4 1/76|2| 603|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-28|24|910|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-24|Rn-BC-WL 2100,18-4 1/76|2| 603|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-29|24|910|Neoplasia malignant|Lower respiratory system|n/a|
2-6-24|Rn-BC-WL 2100,18-4 1/76|2| 603|BCG (bact. Calmette Guerin)||unit code not relevant|Injection, not specified| therapeutic human dose scaled to rat|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-24-30|24|931|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-6-25|Rn-WI-WL 1000,28-8 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-25-1|25|491|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-25|Rn-WI-WL 1000,28-8 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-25-2|25|535|Other deterministic changes|Lower respiratory system|n/a|
2-6-25|Rn-WI-WL 1000,28-8 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-25-3|25|600|Other deterministic changes|Lower respiratory system|n/a|
2-6-25|Rn-WI-WL 1000,28-8 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-25-4|25|606|Other deterministic changes|Lower respiratory system|n/a|
2-6-25|Rn-WI-WL 1000,28-8 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-25-5|25|791|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-6-25|Rn-WI-WL 1000,28-8 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-25-6|25|791|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-6-25|Rn-WI-WL 1000,28-8 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-25-7|25|799|Hyperplastic changes|Lower respiratory system|n/a|
2-6-25|Rn-WI-WL 1000,28-8 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-25-8|25|799|Neoplasia benign|Lower respiratory system|n/a|
2-6-25|Rn-WI-WL 1000,28-8 4/77|2| 144|wine||unit code not relevant|Ingestion in food or water| ad lib. cont.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-25-1|25|491|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-6-25|Rn-WI-WL 1000,28-8 4/77|2| 144|wine||unit code not relevant|Ingestion in food or water| ad lib. cont.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-25-2|25|535|Other deterministic changes|Lower respiratory system|n/a|
2-6-25|Rn-WI-WL 1000,28-8 4/77|2| 144|wine||unit code not relevant|Ingestion in food or water| ad lib. cont.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-25-3|25|600|Other deterministic changes|Lower respiratory system|n/a|
2-6-25|Rn-WI-WL 1000,28-8 4/77|2| 144|wine||unit code not relevant|Ingestion in food or water| ad lib. cont.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-25-4|25|606|Other deterministic changes|Lower respiratory system|n/a|
2-6-25|Rn-WI-WL 1000,28-8 4/77|2| 144|wine||unit code not relevant|Ingestion in food or water| ad lib. cont.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-25-5|25|791|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-6-25|Rn-WI-WL 1000,28-8 4/77|2| 144|wine||unit code not relevant|Ingestion in food or water| ad lib. cont.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-25-6|25|791|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-6-25|Rn-WI-WL 1000,28-8 4/77|2| 144|wine||unit code not relevant|Ingestion in food or water| ad lib. cont.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-25-7|25|799|Hyperplastic changes|Lower respiratory system|n/a|
2-6-25|Rn-WI-WL 1000,28-8 4/77|2| 144|wine||unit code not relevant|Ingestion in food or water| ad lib. cont.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-6-25-8|25|799|Neoplasia benign|Lower respiratory system|n/a|
		
